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INTRODUCTION 
CHOLESTEROL 
 Cholesterol is a waxy, fat-like substance that’s found in all cells of the body. 
All of them have a similar cyclic nucleus resembles the phenanthrene rings (rings 
A, B, C) to which a cyclopentanone ring is attached. The parent nucleus is better 
designated as cyclopentano perhydrophenanthrene. They are divided as sterols, bile 
acids, sex hormones, etc., Our body needs some cholesterol to make hormones, 
vitamin D, and substances that help us to digest foods. Quantity of cholesterol will 
be 140 gms in the body of a man weighing 70 kg. Greater part of the cholesterol in 
the body is synthesized whereas 0.3 gram per day is provided by the average diet. 
Normal concentration of cholesterol in the blood is 140-220 mg per 100 ml of blood. 
Cholesterol travels through the bloodstream in small packages called 
lipoproteins.Two kinds of lipoproteins carry cholesterol throughout our body: low-
density lipoproteins (LDL) and high-density lipoproteins (HDL). Having healthy 
levels of both types of lipoproteins is important. LDL cholesterol  is called “bad” 
cholesterol. A high LDL level leads to a build up of cholesterol in the arteries. HDL 
cholesterol is called “good” cholesterol. This is because it carries cholesterol from 
other parts of the body back to the liver, which removes the cholesterol from our 
body.(1) 
 
Chemistry: 
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 It is a white, waxy, solid associated with fats and chemically different from 
 them. 
 It has apparent nucleus which is said to be cyclopentanoperhydro 
 phenanthrene nucleus. 
 It has a hydroxyl group at C3, an unsaturated bond at C5-C6, two methyl 
 groups at C10 and C13 and 8 carbon paraffin side chains attached to C17. 
 It is an alcohol. 
 It occurs free and combined with fatty acids by ester linkage at the 
 hydroxyl group. 
 Cholesterol in ester form often reffered as ‘bound’ cholesterol esters 
 (CE).These are normally rich in linoleic acid.(2) 
 
FUNCTIONS OF CHOLESTEROL  
 Cholesterol serves a variety of functions in the human body. This includes:  
manufacture of steroids, or cortisone-like hormones, including vitamin D and the 
sex hormones testosterone, estrogen and cortisone. This in turn controls a myriad 
of bodily functions.(2) 
 Assisting the liver in the manufacture of bile acids, which is essential for 
 digestion and absorption of fat-soluble vitamins such as vitamin A, D, E 
 and K. 
 Formation of the myelin sheath, a neuron consisting of fat-containing cells 
that insulate the axon from electrical activity. This ensures proper function 
of our brain cells by aiding route of electrical impulses. The absence of 
cholesterol might lead to loss of memory and difficulty in focusing. 
 As a cell to interconnect "lipid molecules", which are needed to stabilize 
 our cell membranes. 
 As a source of energy. 
 Maintenance of our body temperature 
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 Protection of internal organs 
  Modulation the fluidity of cell membranes 
 
Factors Affecting Blood Cholesterol Levels 
 Many factors determine whether your blood cholesterol level is high or low. 
The following are the most important: (2) 
Heredity  
 Your genes partly determine the amount of cholesterol your body makes, 
and high blood cholesterol can run in families.  
 
Diet  
 There are two nutrients in the foods you eat that can increase your blood 
cholesterol level: saturated fat and cholesterol. Saturated fat is a type of fat found 
mostly in foods that come from animals. Cholesterol comes only from animal 
products. Saturated fat raises your cholesterol level more than anything else in the 
diet. Reducing the amounts of saturated fat and cholesterol you eat is an important 
step in reducing your blood cholesterol levels.  
Weight 
 Excess weight tends to increase blood cholesterol levels. If you are 
overweight and have high blood cholesterol, losing weight may help you lower it.  
 
Exercise  
 Regular physical activity may help to lower LDL-cholesterol and raise 
desirable HDL-cholesterol levels.  
 
Age and Gender  
 Before menopause, women have total cholesterol levels that are lower than 
those of men the same age. Pregnancy raises blood cholesterol levels in many 
women, but blood cholesterol levels should return to normal about 20 weeks after 
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delivery. As women and men get older, their blood cholesterol levels rise. In 
women, menopause often causes an increase in their LDL-cholesterol levels. Some 
women may benefit from taking estrogen after menopause, because estrogen lowers 
LDLs and raises HDLs.  
 
Alcohol  
 Intake increases HDL-cholesterol. It is not known whether it also reduces 
the risk of heart disease. Drinking too much alcohol can certainly damage and liver 
and heart muscle and cause other health problems. Because of these risks, you 
should not drink alcoholic beverages to prevent heart disease.  
 
Stress  
 Over the long term, stress has not been shown to raise blood cholesterol 
levels. The real problem with stress may be how it affects your habits. For example, 
when some people are under stress they console themselves by eating fatty foods. 
The saturated fat and cholesterol in these foods probably cause higher blood 
cholesterol, not the stress itself. 
Synthesis of cholesterol: 
 Liver is the principle organ for cholesterol synthesis. Other tissues like skin, 
ovary, intestine and testis are also capable for cholesterol synthesis. The microsomal 
and cytosol fraction of the cell are involved in the cholesterol synthesis. One 
interesting point is that brain of new born child can synthesize cholesterol but adult 
brain cannot.(2) 
 
 Body cholesterol is primarily of endogenous origin and its homeostasis 
involves the movement of cholesterol between peripheral tissues and liver. 
 
 
The liver regulates 
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 de novo synthesis of cholesterol 
 Excretion of cholesterol into bile directly or in the form of bile salts. 
 Cholesterol discharge into blood as very low density lipoproteins (VLDL). 
 Modulation of receptor-mediated cholesterol uptake. 
 Formation of cholesterol esters and the storage of cholesterol. 
 Intestine controls cholesterol absorption and excretion through faeces. 
 Biosynthesis of cholesterol can occur in five stages 
 Six carbon compound, mevalonate, is synthesized from acetyl-CoA 
 Formation of isoprenoid units (five membred ring structures) occurs from 
 mevalonate by the loss of CO2. 
 Six of these units combine to form a thirty carbon compound named 
 squalene (C30H50) 
 Cyclization of squalene occurs and forms a parent steroid called lanosterol. 
 After many steps cholesterol (C27H46O) is formed from lanosterol with the 
 loss of three methyl groups. 
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Pathway for cholesterol synthesis 
 
Transportation of cholesterol: 
 Lipids are transported in the circulation packaged in lipoproteins. The 
clinical relevance of blood lipid levels is that abnormal levels of lipids in certain 
lipoproteins are linked to an increase risk of atherosclerosis. Atherosclerosis is a 
cardiovascular disease in which lipids and inflammatory cells accumulate in 
plaques within the walls of blood vessels. As a result, vessel walls are narrowed and 
clots may form, impeding blood flow and oxygen delivery and causing tissue injury. 
Heart disease occurs because the coronary arteries supplying the heart are a major 
site where atherosclerotic plaques form.(3) 
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 The liver is central to the regulation of cholesterol levels in the body. Not 
only does it synthesize cholesterol for export to other cells, but it also removes 
cholesterol from the body by converting it to bile salts and putting it into the bile 
where it can be eliminated in the feces. Furthermore, the liver synthesizes the 
various lipoproteins involved in transporting cholesterol and other lipids throughout 
the body. Cholesterol synthesis in the liver is under negative feedback 
regulation.  Increased cholesterol in a hepatocyte leads to decreased activity of 
HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. 
  
Types of Lipoproteins 
 Lipoproteins are particles that contain triacylglycerol, cholesterol, 
phospholipids and amphipathic proteins called apolipoproteins. Lipoproteins can be 
differentiated on the basis of their density, but also by the types of apolipoproteins 
they contain. The degree of lipid in a lipoprotein affects its density—the lower the 
density of a lipoprotein, the more lipid it contains relative to protein. The four major 
types of lipoproteins are chylomicrons, very low-density lipoprotein (VLDL), low-
density lipoprotein (LDL), and high-density lipoprotein (HDL).(4) 
 The figure below summarizes the fates of lipoproteins produced by the liver.  
 
 
 
 
 
 
Fate of lipoproteins in Liver. 
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Chylomicrons and VLDL deliver TAG to cells in the body 
 Two types of lipoproteins are triglyceride-rich: the chylomicrons and 
VLDL. Chylomicrons are synthesized by enterocytes from lipids absorbed in the 
small intestine. VLDL is synthesized in the liver. The function of these lipoproteins 
is to deliver energy-rich triacylglycerol (TAG) to cells in the body (pink pathway). 
TAG is stripped from chylomicrons and VLDL through the action of lipoprotein 
lipase, an enzyme that is found on the surface of endothelial cells. This enzyme 
digests the TAG to fatty acids and monoglycerides, which can then diffuse into the 
cell to be oxidized, or in the case of an adipose cell, to be re-synthesized into TAG 
and stored in the cell.  
LDL delivers cholesterol to cells in the body 
  As VLDL particles are stripped of triacylglycerol, they become more dense. 
These particles are remodeled at the liver and transformed into LDL. The function 
of LDL is to deliver cholesterol to cells, where it is used in membranes, or for the 
synthesis of steroid hormones (blue pathway). Cells take up cholesterol by receptor-
mediated endocytosis. LDL binds to a specific LDL receptor and is internalized in 
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an endocytic vesicle. Receptors are recycled to the cell surface, while hydrolysis in 
an endo lysosome releases cholesterol for use in the cell. 
HDL is involved in reverse cholesterol transport 
 Excess cholesterol is eliminated from the body via the liver, which secretes 
cholesterol in bile or converts it to bile salts. The liver removes LDL and other 
lipoproteins from the circulation by receptor-mediated endocytosis. Additionally, 
excess cholesterol from cells is brought back to the liver by HDL in a process known 
as reverse cholesterol transport (green pathway). HDL (or really, the HDL 
precursor) is synthesized and secreted by the liver and small intestine. It travels in 
the circulation where it gathers cholesterol to form mature HDL, which then returns 
the cholesterol to the liver via various pathways. 
Cholesterol esterase: 
 Dietary cholesterol comprised of free and esterified cholesterol.In diets rich 
in meats, significant percent of cholesterol is esterified. Hydrolysis of cholesteryl 
ester in the lumen is catalysed by cholesterol esterase (CEase). 
 
 Cholesterol esterase is an acid lipase, which is synthesized in the pancreas, 
catalyses the hydrolytic cleavage of cholesterol, sterol esters and triglycerides. 
 
 The name pancreatic cholesterol esterase is ascribed to the only enzyme in 
the pancreas that hydrolyzes cholesterol esters to unesterified cholesterol and free 
fatty acids. However, investigations over a period of more than 30 years revealed 
that a protein with similar properties can also be purified from homogenates of 
several other tissues and body fluids and that enzyme is a nonspecific lipase capable 
of hydrolysing cholesteryl esters, vitamin esters, triacylglycerol, phospholipids, and 
lysophospholipids.(5) 
 At the onset of these investigations, it was not clear whether these various 
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enzyme activities were properties of the same protein. Thus, this enzyme was 
named nonspecific lipase, phospholipase A1 lysophospholipase, bile-salt-stimulated 
lipase, bile salt-dependent lipase, carboxyl ester lipase, and carboxyl ester 
hydrolase.(5) 
 Sequence comparison with other protiens also revealed that this enzyme is 
responsible for the lipoamidase activity in milk, which may account for its ability 
to hydrolyse the physiological lipoamide substrate ceramide. 
Nomenclature of this enzyme was made based on the various substrates of this 
enzyme. 
 Most commonly used name carboxyl ester lipase (CEL), based on the 
 general reactivity of with lipids containing carboxyl ester bonds. 
 Cholesterol esterase or cholesterol ester lipase, due to its documented 
 physiological function as a cholesteryl ester hydrolase. 
 Bile-salt-stimulated or bile salt dependent lipase, based on unique bile salt 
 dependency. 
 Cholesterol esterase has received most attention as having a potential role 
in cholesterol absorption. CEase has broad substrate specificity, hydrolysing tri-, 
di- and mono-glycerides and phospholipids in vitro. It also hydrolyzes cholesterol 
esters, which form a part of dietary cholesterol and cannot be engrossed without 
prior hydrolysis to free cholesterol. As such, it is one of the essential enzymes that 
mediate absorption of dietary lipids through the intestinal wall into the blood 
stream. A number of studies have recommended a possible role for CEase in the 
absorption of free cholesterol at the brush border membrane of the small intestine, 
through a CEase gene.(5) 
 
Synthesis of cholesterol esterase 
 Major tissues for synthesis of this enzyme are acinar cells of exocrine 
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pancreas and lactating mammary glands. 
 Enzyme synthesized by the pancreas is hoard in zymogen granules and is 
secreted with the pancreatic juice in a process stimulated by the gastric 
hormones such as cholecystokinin, secretin and bombesin. CEase mixes 
with the bile salt in the lumen of digestive tract and becomes active enzyme 
which catalyses nutrient digestion and absorption through GIT. 
 Enzyme produced from the lactating mammary glands secreted as a major 
constituent of milk proteins and reaches the digestive tract of the infants, 
which plays a role in nutrient digestion and absorption in them. 
 Low but significant levels are also synthesized in other tissues like liver, 
eosinophils, endothelial cells and macrophages. Physiological function of 
this enzyme synthesized outside digestive tract is unknown.(5) 
 
 Diseases caused due to high cholesterol levels 
             Hyperlipidemia is a main cause of atherosclerosis and atherosclerosis 
associated conditions such as ischemic cerebro-vascular disease, peripheral 
vascular disease (PVD) and coronary-heart disease (CHD).Although the prevalence 
of these atherosclerosis associated events has decreased in United States, these 
conditions still account for the majority of fatality and morbidity between middle-
aged and older people. The occurrence and complete number of annual events will 
raise over the next decade because of the aging and epidemic of obesity of the U.S. 
population. 
          Hyperlipidemia (hypercholesterolemia), Dyslipidemias and low levels of 
HDL cholesterol are main basis of increased atherogenic risk. Both genetic 
disorders and lifestyle (sedentary behavior, high calorific diets) add to the 
dyslipidemias perceived in developed countries around the world. Drug therapy 
like,3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase inhibitors, 
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the statins which are mainly efficient and  best tolerated drugs currently in the use 
for treating dyslipidemia, nicotinic acid (niacin), bile acid-binding resins, fibric acid 
derivatives and the cholesterol absorption inhibitor ‘ezetimibe’ were the other drugs 
used for this treatment.(2) 
OBESITY 
 Obesity is a medical condition in which excess body fat has accumulated to 
the extent that it may have a negative effect on health. People are generally 
considered obese when their body mass index (BMI), a measurement obtained by 
dividing a person's weight by the square of the person's height, is over 30 kg/m2, 
with the range 25–30 kg/m2 defined as overweight. Some East Asian countries use 
lower values. Obesity increases the likelihood of various diseases and conditions, 
particularly cardiovascular diseases, type 2 diabetes, obstructive sleep apnea, 
certain types of cancer, osteoarthritis and depression.(6) 
 
 Obesity is most commonly caused by a combination of excessive food 
intake, lack of physical activity, and genetic susceptibility. A few cases are caused 
primarily by genes, endocrine disorders, medications, or mental disorder. The view 
that obese people eat little yet gain weight due to a slow metabolism is not generally 
supported. On average, obese people have a greater energy expenditure than their 
thin counterparts due to the energy required to maintain an increased body mass.  
 Obesity is mostly preventable through a combination of social changes and 
personal choices. Changes to diet and exercising are the main treatments. Diet 
quality can be improved by reducing the consumption of energy-dense foods, such 
as those high in fat and sugars, and by increasing the intake of dietary fiber. 
Medications may be taken, along with a suitable diet, to reduce appetite or decrease 
fat absorption. If diet, exercise, and medication are not effective, a gastric balloon 
or surgery may be performed to reduce stomach volume or bowel length, leading to 
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feeling full earlier or a reduced ability to absorb nutrients from food. 
 Obesity is a medical condition in which excess body fat has accumulated to 
the extent that it may have an adverse effect on health.It is defined by body mass 
index (BMI) and further evaluated in terms of fat distribution via the waist–hip ratio 
and total cardiovascular risk factors.BMI is closely related to both percentage body 
fat and total body fat. In children, a healthy weight varies with age and sex. Obesity 
in children and adolescents is defined not as an absolute number but in relation to a 
historical normal group, such that obesity is a BMI greater than the 95th percentile. 
The reference data on which these percentiles were based date from 1963 to 1994, 
and thus have not been affected by the recent increases in weight.BMI is defined as 
the subject's weight divided by the square of their height and is calculated as 
follows. 
B=m/h2 
where m and h are the subject's weight and height respectively. 
 
 BMI is usually expressed in kilograms per square metre, resulting when 
weight is measured in kilograms and height in metres. To convert from pounds per 
square inch multiply by 703 (kg/m2)/(lb/sq in). 
 The most commonly used definitions, established by the World Health 
Organization (WHO) in 1997 and published in 2000, provide the values listed in 
the table. 
Table-1 Body Mass Index 
BMI (kg/m2) 
Classification 
From up to 
<18.5 <18.5 Underweight 
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18.5 18.5 normal weight 
25.0 25.0 Overweight 
30.0 30.0 class I obesity 
35.0 35.0 class II obesity 
40.0 40.0 class III obesity 
 
 Some modifications to the WHO definitions have been made by particular 
organizations. The surgical literature breaks down class II and III obesity into 
further categories whose exact values are still disputed. 
 Any BMI ≥ 35 or 40 kg/m2 is severe obesity. 
 A BMI of ≥ 35 kg/m2 and experiencing obesity-related health conditions  
            or ≥40–44.9 kg/m2 is morbid obesity. 
 A BMI of ≥ 45 or 50 kg/m2 is super obesity. 
Causes and mechanisms of obesity 
Energy output: 
 The usual cause of obesity is an unbalance between energy intake and 
output. There are indeed intricate weight-regulating mechanisms that act upon the 
Body's energy stores. The latter can in effect be 'destored' when the body needs 
them, thereby compensating for a lack of energy intake compared to one's needs. 
 
 The daily energy output is made up of three entities: 
Basic metabolism:  
 This is the minimal output necessary for the body to remain alive. It depends 
essentially on the lean mass (which encompasses mostly the muscles) and 
represents 70% of the total energy output.  
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Physical activity: 
 This of course varies greatly, from the sedentary person to the hard labourer. 
It accounts on average for 20% of the total energy output. Because of the excess 
weight an obese person carries around, even when exerting only moderate physical 
activity he will be using up more energy than someone with normal weight. 
 
 It is therefore easy to understand why physical activity alone will not enable 
an obese person to achieve maximum weight loss. However, if the main element of 
a correctly balanced diet is an overall decrease in food intake, sport will play a 
significant role as it will assist in maximising its effects. Sport has moreover been 
shown to be beneficial in the long term as a means to prevent a relapse.  
 
Thermogenesis: 
 This phenomenon results from the metabolism of food - absorption and 
storage - after meals. It represents 10% of the total energy output. A certain amount 
of the calories absorbed during a meal are therefore immediately 'burnt off' by 
digestion. This explains why jumping a meal does not fit into sensible dieting 
recommendations. 
 
  
 Taking into account the above facts, and coupling these the notion that 
moderate but constant overeating can lead to a state of obesity, it is easy to 
understand the difficulties to obtain good therapeutic results with diets. In 
particular, it is known that only to maintain their lean body mass - in particular with 
regard to the muscular component - obese people are dependent on hypercalorific 
food rations.  
 
 There is a true inequality for weight-gain in normal subjects, which can 
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explain a feeling of unfairness. The famous experiences of Sims, carried on with 
inmates, are very relevant: some of them had a high-calorie diet (more than 10000 
calories per day, whereas the normal intake is an average of 2200 calories). Only a 
minority of them could gain some weight (more than 6 kg), precisely the ones that 
had a family background of obesity, which is an acknowledged cause of obesity. 
 
Factors that encourage obesity 
 The above statements clearly show how obesity in itself is a complex 
phenomenon. Without getting too specific, the main factors that induce obesity can 
be roughly divided into the following main groups.(6)  
 
Factors related to Food 
 These intervene at three levels. 
 
Excess intake (quantity):   
 Food intake must vary according to a person's physical activity. A sedentary 
person will use up much less energy than a labourer. Too much food and not enough 
physical activity will inevitably lead to a person putting on excess weight. 
 
Imbalance in intake (quality):  
 Without going into too much detail, we know that fat (lipids) plays an 
important part in creating an imbalance. Excess intake of so-called fast-acting 
sugars (sweetened drinks, chocolate, etc.) is also detrimental. In effect, these sugars 
are stored as fat and are then difficult to get rid off. 
 
Eating disorders:  
 These include the absence of regular meal times, a problem characteristic of 
modern industrialised countries; and an overall poor lifestyle incompatible with 
regular meals. In a few cases there can be an alteration of the central nervous system 
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regulating the appetite, but this is only true for a small minority of people.  
 
Factors related to energy output 
 This relates to the state of being sedentary in the large sense of the term, and 
also to the change from an active to a sedentary lifestyle. 
 
Genetic factors 
 There is certainly a genetic predispostition (linked to numerous genes, not 
just one) which makes an individual, or members of a same family more susceptible 
to becoming obese within a given environment. We should not, however, conclude 
that obesity is a genetic illness, except for very rare and specific cases such as the 
Prader-Willi syndrome which affects adolescents and combines obesity and mental 
deficiency. 
 
 Psychologic factors 
 As described in the chapter on the psychological aspects of obesity, there is 
no such thing as a typical psychological profile for an obese person. In other words, 
there is no specific trait of character or anatomy of the psychism that predisposes 
towards obesity. On the other hand, certain psychological states such as depression 
or stress can influence weight gain. Matters are further complicated by the fact that 
weight gain in turn can lead to a number of abnormal psychological traits which 
could wrongly be interpreted as the cause of obesity. 
 
Social and cultural factors 
 It is wrong to infer that poverty predisposes towards obesity, however an 
inverse relationship between income and obesity can be observed in all western 
countries. This can be explained by different eating habits (more fat in the diet for 
the poorer classes of the population) and unequal rights to healthcare. Hardly one 
century ago obesity was considered as a sign of wealth and prosperity. Today the 
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tendency is towards the opposite, where the rich can be seen ' taking care of their 
body '. It is in fact the life styles that have been adopted today which exert a bad 
influence on eating habits : global reduction in physical activity due to improved 
means of transport which lead to people walking less, a reduction of sport activities 
in schools, an increase in fast-food restaurants and vendors of high calorific sweet 
drinks and foods, the disappearance of regular eating times, snacks eaten in front of 
the television, and more recently videos and an increased use of computers for 
recreation means. 
 
TYPES OF OBESITY 
1.  Inactivity Obesity  
 It is no secret that a lack of physical activity can cause you to become 
overweight. In this type of obesity, once-strong parts of the body quickly gain fat 
and become unhealthy. 
2. Food Obesity  
 If you overeat, and particularly if you overindulge in unhealthy foods, you 
may suffer from food obesity. Excessive sugar intake can also cause food obesity, 
which may lead to accumulation of fat around the middle part of the body. 
3.  Anxiety Obesity  
 Anxiety or depression can often lead to overeating and accumulation of fat 
in the body, since the body must constantly survive in fight-or-flight mode. To treat 
this type of obesity, you must control your anxiety. Common treatments include 
medication, a decrease in caffeine intake, and herbs. 
 
4.  Venous Obesity   
 Venous circulation is one obesity cause that is genetic in nature, rather than 
habitual in nature. if anyone in your family suffers from venous circulation, you run 
the risk of the same condition. This type of obesity is particularly common in 
pregnancy. Exercise is the best solution for this problem. 
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5. Atherogenic Obesity  
 People whose fat tends to accumulate in the stomach area often suffer from 
atherogenic obesity. This is a particularly dangerous condition since it can affect 
your other organs and lead to breathing problems. It is extremely important to avoid 
drinking alcohol if you have atherogenic obesity. 
 
6.  Gluten Obesity  
 You are likely no stranger to the many health problems that gluten can 
cause. In fact, gluten can actually cause obesity. This type of weight gain is most 
common in women. It is often spotted during periods of hormonal change, like 
puberty, pregnancy, and menopause. 
 
Hyperlipidaemia 
 Lipid is another word for fat. Lipids are easily stored in the body and serve 
as a source of energy. Cholesterol and triglycerides are lipids. When the 
concentration of triglycerides or cholesterol in your blood is too high, it is called 
hyperlipidaemia. Having a lipid level that is too high increases your risk of heart 
attacks and strokes.(3) 
 
 A health Bloor (1943) has proposed the following classification of lipids 
based on their chemical composition. 
 
A.  Simple lipids or Homolipids.  
 These are esters of  fatty acid with farious alcohols. 
 
1.  Fats and oils (triglycerides, triacylglycerols). 
 These are esters of fatty acids with a trihydroxy alcohol,glycerol. A fat is 
solid at ordinary room temperature wheras an oil is liquid. 
 
2.  Waxes 
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 These are esters of fatty acids with high molecular weight monohydroxy 
alcohols. 
 
B.  Compound lipids or Heterolipids.  
 These are esters of fatty acids with alcohol and possess additional group(s) 
also. 
1. Phospholipids (phosphatids),  
 These are compounds containing, in addition to fatty acids and glycerol, a 
phosphoric acid, nitrogen bases and other substituents. 
 
2. Glycolipids (cerebrosides).  
 These are the compounds of fatty acids with carbohydrates and contain 
nitrogen but no phosphoric acid. The glycolipids also include certain structurally-
related compounds comprising the groups, gangliosides, sulfolipids and sulfatids. 
 
C.  Derived lipids.  
 These are the substances derived from simple and compound lipids by 
hydrolysis. These include fatty acids, alcohols, mono- and diglycerides,steroids, 
terpenes and carotenoids.y diet and medicines can help lower your lipid levels.  
 Glycerides and cholesterol esters, because of their uncharged nature, are 
also called neutral lipids.However, Conn and Stumpf (1976) have traditionally 
classified lipids into following 6 classes : 
1.  Acyl glycerols 
2.  Waxes 
3.  Phospholipids 
4.  Sphingolipids 
5. Glycolipids 
6. Terpenoid lipids including carotenoids and steroids 
Atheroma and cardiovascular diseases 
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 Patches of atheroma are like small fatty lumps that develop within the inside 
lining of blood vessels (arteries). Atheroma is also known as atherosclerosis and 
hardening of the arteries. Patches of atheroma are often called plaques of atheroma. 
 Over months or years, patches of atheroma can become larger and thicker. 
So in time, a patch of atheroma can make an artery narrower. This can reduce the 
blood flow through the artery. For example, narrowing of the heart (coronary) 
arteries with atheroma is the cause of angina. 
 Sometimes, a blood clot (thrombosis) forms over a patch of atheroma and 
completely blocks the blood flow. Depending on the artery affected, this can cause 
a heart attack, a stroke, or other serious problems. 
 Cardiovascular diseases are diseases of the heart (cardiac muscle) or blood 
vessels. However, in practice, when doctors use the term cardiovascular disease 
they usually mean diseases of the heart or blood vessels that are caused by atheroma. 
 In summary, cardiovascular diseases caused by atheroma include angina, 
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heart attack, stroke, transient ischaemic attack (TIA) and peripheral arterial disease. 
In the UK, cardiovascular diseases are a major cause of poor health and the biggest 
cause of death. 
 
Blood levels of cholesterol 
 Cholesterol blood levels are very important but must be considered in an 
overall assessment of your risk of cardiovascular disease .The following blood 
cholesterol levels are generally regarded as desirable: 
 
 Total cholesterol (TChol) - 5.0 mmol/L or less. However, about 2 in 3 adults 
in the UK have a TChol level of 5.0 mmol/L or above. 
 LDL cholesterol: 3.0 mmol/L or less. 
 HDL cholesterol: 1.2 mmol/L or more. 
 TChol/HDL ratio: 4.5 or less. That is, your TChol divided by your HDL 
cholesterol. This reflects the fact that for any given TChol level, the more 
HDL, the better. 
 As a rule, the higher the LDL cholesterol level, the greater the risk to health. 
A blood test only measuring total cholesterol may be misleading. A high total 
cholesterol may be caused by a high HDL cholesterol level and is therefore healthy. 
It is very important to know the separate LDL cholesterol and HDL cholesterol 
levels. 
 Your level of LDL cholesterol has to be viewed as part of your overall 
cardiovascular health risk. The cardiovascular health risk from any given level of 
LDL cholesterol can vary, depending on the level of your HDL cholesterol and on 
any other health risk factors that you may have. Therefore, a cardiovascular risk 
assessment considers all your risk factors together. 
Triglycerides 
 Triglycerides are the main form of fat stored in the body. When you think 
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of fat on your hips or stomach, you're thinking of triglycerides. 
Triglycerides are the end product of digesting and breaking down the bulky fats that 
are present in our food. Any food we eat that isn't used for energy immediately - 
carbohydrates, fat, or protein - is also converted into triglycerides. They are bundled 
into globules and transported through the blood by lipoproteins, like cholesterol. 
The triglycerides are taken up by fat (adipose) cells, to be used for energy if food 
isn't available later. 
Normal levels of lipids 
 Fat chemicals (lipids) are measured in millimoles per litre which is a 
measure of how concentrated they are in 1 litre of blood. It is usually written as 
mmol/L. The following levels are generally considered desirable. However, a 
doctor or nurse will advise on the level for you to aim for. They will consider any 
other diseases or risk factors that you may have  
 
 Total cholesterol (TChol) - 5.0 mmol/L or less. 
 LDL cholesterol after an overnight fast: 3.0 mmol/L or less. 
 HDL cholesterol: 1.2 mmol/L or more. 
 TC/HDL ratio: 4.5 or less. That is, your TChol divided by your HDL 
cholesterol. This reflects the fact that, for any given TChol level, the more 
HDL, the better. 
 Triglycerides (TGs): 1.7 mmol/L or less after an overnight fast. 
 Generally, the higher the LDL cholesterol level, the greater the risk to 
health. However, your level of cholesterol has to be viewed as part of your 
overall cardiovascular health risk. The cardiovascular health risk from any 
given level of cholesterol can vary, depending on the level of your HDL 
cholesterol and on other health risk factors that you may have. 
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Causes of hyperlipidaemia 
 Hyperlipidaemia is often found when people are overweight or have an 
unhealthy diet. It can also be the result of drinking too much alcohol. It can be 
something that you may have inherited through your family genes (known as 
primary) and approximately 1 person in 500 will have this cause. It may be because 
of another medical condition that you may have, such as diabetes, when it is known 
as secondary. Other causes include: 
 
 An underactive thyroid (hypothyroidism). 
 Obstructive jaundice. 
 Cushing's syndrome. 
 Anorexia nervosa. 
 Nephrotic syndrome. 
 Chronic kidney disease. 
Some prescribed medicines can affect your cholesterol level, including: 
 Thiazide diuretics (used to control blood pressure). 
 Glucocorticoids (steroids). 
 Cyclosporine (used after organ transplants). 
 Antiretroviral therapy (used to treat HIV infection). 
 Beta-blockers (used to control heart rate). 
 The combined oral contraceptive pill. 
 Atypical antipsychotics (used in some mental health problems). 
 Retinoic acid derivatives (used in some skin conditions). 
Symptoms of hyperlipidaemia 
 Hyperlipidaemia is often found during routine screening when your doctor 
is trying to assess your risk of having heart attacks or strokes. This may be as part 
of an annual health check if you are over 40 years of age, or if you have a close 
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relative who had these problems at a young age. 
 Usually, the diagnosis is made after a fasting blood test. Fasting means at 
least 12 hours when you have not eaten. You are allowed to drink water. 
There are also changes that may be visible on your body if you have the inherited 
form of hyperlipidaemia.(3) 
 
 Premature arcus senilis - this is a white or grey ring that is visible when 
your doctor looks at the front of your eyes. 
 Tendon xanthomata - these are hard nodules that you may find in the 
 tendons of the knuckles and the Achilles (at the back of your ankle). 
 Xanthelasmas - fatty deposits in the eyelids. 
 
 
 
 
Lowering lipid levels 
 Changing from an unhealthy diet to a healthy diet can reduce a cholesterol 
level. However, dietary changes alone rarely lower a cholesterol level enough to 
change a person's risk of cardiovascular disease from a high-risk category to a 
lower-risk category. However, any extra reduction in cholesterol due to diet will 
help. 
 A healthy diet has other benefits too apart from reducing the level of 
cholesterol. 
Briefly, a healthy diet means: 
 At least five portions, or ideally 7-9 portions, of a variety of fruit and 
 vegetables per day. 
 A third of most meals should be starch-based foods (such as cereals, 
 wholegrain bread, potatoes, rice, pasta), plus fruit and vegetables. 
 Not much fatty food such as fatty meats, cheeses, full-cream milk, fried 
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food, butter, etc. Use low-fat, mono-unsaturated or polyunsaturated spreads. 
 Include 2-3 portions of fish per week, at least one of which should be oily 
(but, if you are pregnant, you should not have more than two portions of oily 
fish a week). 
 Limit salt to no more than 6 g a day (and less for children). 
 If you eat red meat, it is best to eat lean red meat, or eat poultry such as 
 chicken. 
 If you do fry, choose a vegetable oil such as sunflower, rapeseed or olive. 
 Foods that contain plant sterols or stanols can reduce total blood cholesterol 
level and LDL cholesterol by about 10%. There does not seem to be much 
evidence, however, that this has an effect on preventing cardiovascular 
disease. The National Institute for Health and Care Excellence (NICE) 
therefore does not recommend that these products should be used routinely 
until more information is available. 
Antihyperlipidemic Drugs  
Lipid disorders(3,7)  
 Disorders of lipid metabolism are manifest by elevation of the plasma 
concentrations of the various lipid and lipoprotein fractions (total and LDL 
cholesterol, VLDL, triglycerides, chylomicrons) and they result in cardiovascular 
disease and atherosclerosis.  
 
Type of hyperlipidemia 
1.  Primary hyperlipidemia 
2.  Secondary hyperlipidemia 
 
CLASSIFICATION- based on the pattern of lipoprotein on electrophoresis or 
ltracentrifugation.  
 Familial Chylomicronemia (I):increased Chylomicrons due to deficiency 
of lipoprotein lipase or its cofactor. 
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  Familial Hypercholesterolemia (IIA): levels of LDL tend to increase with 
normal VLDL. 
 Familial Combined (mixed)Hyperlipidemia (IIB): elevated levels of 
VLDL, LDL.  
 Familial Dysbetalipoproteinemia (III): Increased IDL resulting increased 
TG and cholesterol levels. 
 
 Familial Hypertriglyceridemia (VI): Increase VLDL production with 
normal or decreased LDL.  
 
 Familial mixed hypertriglyceridemia (V): Serum VLDL and 
chylomicrons are increased  
Secondary hyperlipidemias results from: 
 Liver disease, Biliary disease, Obesity, Hypothyroidism, Diabetes, Diet, 
Alcohol excess, Renal disease (nephrotic syndrome), Drugs (HIV protease 
inhibitors, thiazide diuretics, oral contraceptive steroids) The most severe 
hyperlipidaemias usually occur in patients with concurrent conditions, e.g. diabetes 
Mellitus with one of the primary hyperlipidemias. 
 
Drug therapy: the primary goal of therapy is to: 
 Decrease levels of LDL 
 Increase in HDL 
 
Anti-hyperlipidemic drugs are mainly classified into 5 types (7) 
 HMG CoA REDUCTASE INHIBITORS: E.g. Atorvastatin, Fluvastatin, 
 Lovastatin, Pravastatin, Simvastatin. 
 FIBRATES: E.g. Fenofibrate, Gemfibrozil, Clofibrate 
 Anion –exchange resins( BILE ACID SEQUESTRANTS): E.g. 
 Colesevelam, Colestipol, Cholestyramine 
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 Nicotinic acid: E.g. NIACIN. 
 CHOLESTEROL ABSORPTION INHIBITORS: E.g. Ezetimibe. 
 OTHER DRUGS E.g. Alpha-tocopherol acetate (vitamin E), Omega-3 
 marine triglycerides (Maxepa), Orlistat 
 
 HMG-CoA Reductase Inhibitors (HMGs or statins) Pravastatin , 
Simvastatin , Atorvastatin , Fluvastatin , Lovastatin. (They are most potent LDL 
reducers)  
Mechanism of action of statins 
 Block the rate-limiting enzyme for endogenous cholesterol synthesis, 
hydroxy-methylglutaryl Coenzyme A (HMG CoA) reductase. 
 Increased synthesis of LDL-receptors (upregulation) in the liver 
 Increased clearance of LDL from the circulation 
 Note: Plasma total cholesterol and LDL-cholesterol fall to attain a maximum 
effect 1 month after therapy. 
 
Therapeutic uses:  
 These drugs are effective in lowering plasma cholesterol levels in all types 
of hyperlipidemias However, patients who are homozygous for familial 
hypercholesterolemia lack LDL receptors and, therefore, benefit much less from 
treatment with these drugs. These drugs are often given in combination with other 
antihyperlipidemic drugs 
 
Pharmacokinetics of statins : 
 Pravastatin and fluvastatin are almost completely absorbed after oral 
administration. 
  Oral doses of lovastatin and simvastatin are from 30 to 50 percent 
 absorbed. 
 Pravastatin and fluvastatin are active, whereas lovastatin and simvastatin 
 must be hydrolyzed to their acid forms. 
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 Excretion takes place through the bile and feces 
 Some urinary elimination also occurs. 
 Their half-lives range from 1.5 to 2 hours. 
 
 Note: Because of a circadian rhythm to LDL-receptor synthesis, statins are 
a little more effective if given in the evening rather than in the morning.  
 
Adverse effects 
1.  Transient, and minor abnormality of liver function tests 
2.  Myopathy and rhabdomyolysis (disintegration or dissolution of muscle and 
elevation of muscle enzymes (creatine phosphokinase, CPK),the risk is 
greater in: 
3. In patients with renal insufficiency 
4. In patients taking drugs such as cyclosporine, itraconazole, erythromycin, 
gemfibrozil, or niacin. Plasma creatine kinase levels should be determined 
regularly. 
Drug interactions: 
 The HMG CoA reductase inhibitors may also increase warfarin levels. Thus, 
it is important to evaluate INR  
 
Contraindications: 
 These drugs are contraindicated during pregnancy and in nursing mothers. 
They should not be used in children or teenagers. 
FIBRIC ACID DERIVATIVES (FIBRATES) Bezafibrate Ciprofibrate 
Fenofibrate Gemfibrozil  
Mechanism of action  
 Agonists at PPAR (peroxisome proliferator-activated receptor) ĺ 
expression of genes responsible for increased activity of plasma lipoprotein lipase 
Introduction 
 
 
 
In vitro  Cholesterol Esterase Inhibitory Activity and In vivo 
 Anti-Hyperlipidemic  Activity of Anisomeles malabarica 30 
enzyme ĺ hydrolysis of VLDL and chylomicronsĺ Ļserum TGs.Ĺ clearance of 
LDL by liver & Ĺ HDL. 
 
Therapeutic uses  
 Hypertriglyceridemia (the most effective in reduction TGs) - combined 
hyperlipidemia (type III) if statins are contraindicated  
 
Pharmacokinetic 
 Well absorbed from the gastrointestinal tract 
 Extensively bound to plasma proteins 
 Excreted mainly by the kidney as unchanged drug or metabolites. 
Contraindications 
1.  Where hepatic or renal function is severely impaired (but gemfibrozil has 
been used in uraemic and nephrotic patients without aggravating 
deterioration in kidney function) 
2.  Pregnant or lactating women 
 
Adverse effects 
1.  Gastrointestinal effects 
2.  Lithiasis: Because these drugs increase biliary cholesterol excretion, there 
 is a predisposition to the formation of gallstones. 
 
3.  Myopathy and rhabdomyolysis the risk is greater in: 
  Patients with poor renal Function 
  In patients taking a statin. 
4. Fibrates enhance the effect of co-administered oral Anticoagulants. 
 
Anion – exchange resins (BILE ACID SEQUESTRANTS): Cholestyramine, 
Introduction 
 
 
 
In vitro  Cholesterol Esterase Inhibitory Activity and In vivo 
 Anti-Hyperlipidemic  Activity of Anisomeles malabarica 31 
Colestipol Colesevelam  
 
Mechanism of action: 
  Anion exchange resins bind bile acids in the intestine forming complex 
ĺloss of bile acids in the stools ĺĹ conversion of cholesterol into bile acids 
in the liver. 
  Decreased concentration of intrahepatic cholesterol ĺ compensatory 
increase in LDL receptors ĺĹ hepatic uptake of circulating LDL ĺ Ļ serum 
LDL cholesterol levels. 
 
Therapeutic uses: 
1.  In treatment of type IIA and IIB hyperlipidemias (along with statins when 
 response to statins is inadequate or they are contraindicated). 
2. Useful for Pruritus in biliary obstruction (Ĺ bile acids). 
Pharmacokinetics:  
 Orally given but neither absorbed nor metabolically altered by intestine, 
totally excreted in feces.  
 
Adverse effects: 
1.  Gastrointestinal effects: constipation (most common), nausea, and 
 flatulence, anorexia, diarrhea, these effects are dose-related. 
2.  Impaired absorptions: At high doses, cholestyramine and colestipol impair 
the absorption of the fat-soluble vitamins (A, D, E, and K). 
 
 Note: Colesevelam has fewer gastrointestinal side effects and not impaired 
absorption of the fat-soluble vitamins (A, D, E, and K).  
 
Drug interactions:  
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 Tetracycline, warfarin, digoxin, thiazide diuretics, phenobarbitone and 
thyroid hormones should be taken 1 h-2h before or 4 h- 6 h after colestyramine to 
avoid impairment of their absorption (Because the drug binds anions) 
Niacin (nicotinic acid) 
 
Mechanism of action: 
 It is a potent inhibitor of lipolysis in adipose tissues ĺ Ļ mobilization of 
 FFAs (major precursor of TGs) to the liver ĺ Ļ VLDL (after few hours). 
 Since LDL is derived from VLDL so Ļ VLDL ĺ Ļ LDL (after few hours). 
 Ĺ HDL levels 
 Ļ Endothelial dysfunction ĺĻ thrombosis. 
 
Therapeutic uses:  
 Niacin lowers plasma levels of both cholesterol and triacylglycerol. 
Therefore, it is particularly useful in the treatment of familial hyperlipidemias. 
Niacin is also used to treat other severe hypercholesterolemias, often in combination 
with other antihyperlipidemic agents. In addition, it is the most potent 
antihyperlipidemic agent for raising plasma HDL levels, which is the most common 
indication for its clinical use.  
 
Pharmacokinetics:  
 Niacin is administered orally. It is converted in the body to nicotinamide, 
which is incorporated into the cofactor nicotinamide-adenine dinucleotide (NAD+). 
Niacin, its nicotinamide derivative, and other metabolites are excreted in the urine. 
[Note: Nicotinamide alone does not decrease plasma lipid levels.]  
 
Adverse effects: 
1.  Cutaneous flush most common side effects accompanied by an 
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uncomfortable feeling of warmth and pruritus. Administration of aspirin 
prior to taking niacin decreases the flush, which is prostaglandin mediated. 
The sustained-release formulation of niacin, which is taken once daily at 
bedtime reduces bothersome initial adverse effects. 
2.  Nausea and abdominal pain. 
3.  Hyperuricemia and gout ( Niacin inhibits tubular secretion of uric acid ) 
4.  Impaired glucose tolerance 
5.  Hepatotoxicity 
Cholesterol absorption inhibitors  
Ezetimibe 
 Selectively inhibits intestinal absorption of dietary and biliary cholesterol in 
the small intestine ĺ Ļ in the delivery of intestinal cholesterol to the liver 
ĺ Ļ of hepatic cholesterol stores ĺ Ĺ clearance of cholesterol from the 
blood. 
 Ezetimibe lowers LDL cholesterol and triacylglycerols 
 Increases HDL cholesterol. 
 
Pharmacokinetic 
 Metabolized in the small intestine and liver via glucuronide conjugation (a 
Phase II reaction), with subsequent biliary and renal excretion. 
 Both ezetimibe and ezetimibe-glucuronide are slowly eliminated from 
 plasma, with a half-life of approximately 22 hours. 
 Ezetimibe has no clinically meaningful effect on the plasma concentrations 
of the fat-soluble vitamins A, D, and E. Patients with moderate to severe 
hepatic insufficiency should not be treated with ezetimibe. 
 [Note:] A formulation of ezetimibe and simvastatin has been shown to 
 lower LDL levels more effectively than the statin alone.  
 
Combination drug therapy 
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 Bile acid resins can be safely combined with statins or nicotinic acid (Ļ 
LDL, VLDL cholesterol levels respectively). 
 Ezetimibe + statins ĺ synergistic effects. 
 Fibrates and statins are CI ĺ myopathy. 
 Nicotinic acid and statins (must be cautiously used) ĺ myopathy 
 
 
 
OTHER DRUGS:  
Alpha-tocopherol acetate (vitamin E)  
 Has no effect on lipid levels but is a powerful antioxidant. Considerable 
evidence points to oxidation of LDL as an essential step in the development of 
atheroma, and therefore interest has centred on the role of either endogenous or 
therapeutic vitamin E in prevention of atheroma.  
 
Omega-3 marine triglycerides (Maxepa) contain  
 The triglyceride precursors of two polyunsaturated fatty acids derived from 
oily fish. They have no place in treating hypercholesterolaemia. Some patients with 
moderate to severe hypertriglyceridaemia may respond to oral use, although 
LDLcholesterol may rise.  
Orlistat, a weight-reducing agent  
 It is pancreatic lipase inhibitor, lowers the Glycaemia of diabetes mellitus 
to a degree that accords with the weight loss, and improves Hyperlipidmia .There 
is a risk of steatorrhoea and malabsorption of Fat-soluble vitamins A, D and E. 
FDA approved new anti-hyperlipidemic drugs  
 Food and drug administration (FDA), U.S. approved some new drugs for 
the treatment of hyperlipidemia associated diseases. They are as follows: 
 I.  Livalo (Pitavastatin) 
 II.  Juxtapid (Lomitapide) 
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 III.  Kynamro (Mipomersen) 
 IV.  Vascepa (Icosapent ethyl) 
 
Medicinal plants used in the treatment of hyperlipidemia(7) 
 Numbers of plant species were reported to possess anti-hyperlipidemic 
activity like Abelmoschus esculentus, Achyranthus aspera, Allium sativa, Bauhinia 
variegata, Curcuma longa and the other plants and plant constituents which were 
reported to posses anti-hyperlipidemic activity are listed in Table-2 . 
Table 2:     List of medicinal plants having Hypolipidemic activity 
Plant name Part used 
Abelmoschus esculentus Whole plant 
Achyranthus aspera Roots 
Aegle marmelos Leaf 
Allium cepa Fresh bulbs 
Allium sativum Fresh fruits 
Alstonia scholaris Leaves 
Amaranthus viridis Leaves 
Andrographis serpyllifolia Roots 
Anethum graveolens Essential oil 
Asparagus racemosus Roots 
Bauhinia Variegata Roots & Stems 
Cassia fistula Legume 
Catharanthus roseus Leaves 
Curcuma longa Rhizome 
Cymbopogon citrates Leaves 
Eclipta prostate Leaves 
Garcinia combogia Peel of matured fruits 
Glyccyrrhiza glabra Roots 
Hibiscus rosa sinesis Root 
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Morus alba Leaves 
Nelumbo nucifera Leaves 
Ocimum basilicum Whole plant 
Pongamia pinnata Pods, flowers 
Ruta graveolens Leaves, Whole plant 
Terminalia chebula Pericarp 
Zingiber officinale Rhizome 
Table 3: List of the Phytoconstituents having Hypolipidemic activity 
Biological source Phytoconstituents 
Allium cepa S-methyl cysteine sulfoxide 
Atrium lappa L. Inulin 
Avena sativa L. Mono and oligosachcharide 
Bupleurum chinense DC Triterpine 
Citrus lemon L. Pectin, citrus flavonoids 
Cyamposis tetragonolobus(L) Gums 
Emblica officinalis Fixed oil and volatile oil 
Ginkgo biloba L. Polyphenolic compounds, Flavonoids 
Medicago sativa L. Saponins 
Plantago lanceolata L. Metamucil 
 
Need for Natural Hypolipidemic agents 
 The use of statins in the treatment of Hyperlipidemia causes concern in both 
patients and physicians about the safety associated with such medications. Muscle 
toxicity or myopathy, is a common adverse effect of this class of drugs. Myopathy 
progressing to rhabdomyolysis and renal failure is the most serious side effect 
associated with all statins either in monotherapy or in combination therapy and 
appears to be doserelated. As statins therapy is for a long term basis, there may be 
a risk of chronic toxic effects like carcinogenic, teratogenic and mutagenic over a 
life time of use. Till date, there are very less natural medications available in the 
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market to treat hyperlipidemia. Therefore it is a need of the day to search for natural 
medicaments because of their fewer side effects and less expensive as compared 
with synthetic drugs. So, numerous studies are needed to explore the anti-
hyperlipidemic activity of herbs. This may, at least in part, help future studies to 
screen the newer anti-hyperlipidemic molecules.(7) 
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PLANT PROFILE 
 Anisomeles malabarica (8) 
 
 Plant name :  Anisomeles malabarica(L.)R.Br 
 Synonym   :  Nepeta malabarica L. 
 Family       : Lamiaceae 
 
Vernacular names: 
 Anisomeles malabarica are locally known as Malabar catmint in English,  
 Hindi            :     Kalpanath,  Codhara, Gopoli  
 Irula              :     Kannu thumbai  
 Kannada      :     Karitumbi, Gandubirana Gida   
 Konkani       :     Kaktumbo   
 Malayalam  :   Karintumpa, Karithumba, Karimthumba, Perumtumpa 
 Marathi        :     Gojibha   
 Oriya           :     Vaikuntha    
 Sanskrit       :     Mahadronah, Vaikunthah   
 Tamil          : Aruvaachadachi, peyimarutti  
 Telugu :     Mogabheri or Moga- biran. 
 
 TAXONOMIC CLASIFICATION: 
 Division           :  Spermatophyta  
 Sub-division   :  Angiospermae  
 Class                :  Dicotyledone  
 Sub-class         :  Gamopetalae  
 Series               : Bicarpellate  
 Order               : Lamiales  
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 Family              :  Labiatae or Lamiaceae  
 Genus               :  Anisomeles   
 Species             :  Malabarica R.Br.  
 Botanical name: Anisomeles malabarica(L) R. Br.   
 
Biological source: 
 Young leaves 
 
Distribution: 
 Anisomeles malabarica are of Asiatic origin was limited in its distribution 
and is found only in south India, Srilanka and Australia.(8) 
 
Parts used: 
 All parts of the plant 
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Anisomeles malabarica plant 
 
Description: 
 Malabar Catmint is a shrubby herb, 0.5-1.5 m tall. Stems are tetragonous, 
densely villous or woolly. Leaves are ovate to oblong, 3-8 cm x 1.5-3 cm, densely 
woolly beneath, sparsely hirsute above, hairs 4-celled, petiole 0.5-2.5 cm long, 
softly woolly. Inflorescence is a single terminal spike, calyx 8.5 mm x 6 mm, 
longest teeth 3-4 mm long, in fruit 8-10 mm long, teeth hairy inside. Flower up to 
1.8 cm long, lower lip about 12 mm x 4 mm, lilac or pale blue, filaments almost at 
same level, about 8 mm long, style about 1.3 cm long. Nutlets are cylindrical, 1.3 
mm x 0.9 mm. 
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Chemical constituents: 
 Plant (roots, stems, leaves and flowers) yield essential oil, anisomelic acid, 
ovatodiolide, diterpenes - malabaric acid, anisomelyl acetate, anisomellol, 
anisomelolide, crisilineol, betulinic acid and Beta-sitosterol.(8,9) 
 
Medicinal uses: 
 The whole plant, especially the leaves and the roots are used as astringent, 
carminative, febrifuge and tonic. 
 
 TRADITIONAL  AND  ETHANOBOTANICAL USES(9) 
 Ethnobotanically, the leaves of A.malabarica are used against convulsions, 
dyspepsia, intermittent fever, colic, boils, tetanus. Anisomeles malabarica is 
useful in halitosis, epilepsy, hysteria, amentia, anorexia, dyspepsia, colic, 
flatulence, intestinal worms, fever arising from teething in children, intermittent 
fever, gout, swelling, diarrhoea and rheumatism.The plant also shows properties 
like antiperotic, diaphoretic, emmenagogue etc. Recently the plant was 
investigated for its herbicidal activity. Stem paste of A.malabarica mixed with 
coconut oil is applied topically over the wounds, and the Leaves are used to treat 
Eczema.The plant is also used in curing various ailments like anticancer, 
allergenic, anthelmintic, antiallergic, antianaphylactic, antibacterial, 
anticarcinomic, antiedemic, antihistaminic, antiinflammatory, antileukemic, 
antinociceptive, antiplasmodial, antiseptic and antiperotic properties. 
A.malabarica is being investigated for its pharmacognostical and various 
biological activities. 
 
REPORTED ACTIVITIES 
 The reported activities of Anisomeles malabarica includes Anti-allergic, 
Anti-anaphylactic, Anti-bacterial, Anti-cancer, Anti-carcinogenic, Anti-
inflammatory, Anti-epileptic potential, Antifertility, Anti-pyretic activity and 
antispasmodic activity.(8,9) 
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REVIEW OF LITERATURE 
 
LITERATURE RELATED TO ANTI HYPERLIPIDEMIC ACTIVITY 
  Huang et al., (2017) reported the dyslipidemic activity of Malus -
toringoides leaves which is traditionally used as a medicine for treating or 
preventing cardiovascular disease in Tibet. In addition to the effect of this 
medicinal plant on thrombosis, they tested its effect on dyslipidemia in a 
hypolipidemic rat model. Serum levels of total cholesterol (TC), triglycerides 
(TG), low- and high-density lipoprotein cholesterol (LDL-C and HDL-C, 
respectively), as well as the antioxidant capacity of glutathione peroxidase 
(GSHP-X), superoxide dismutase (SOD), and malondialdehyde (MDA) were 
measured at the end of the study. MT significantly reduced serum TC, TG, and 
LDL-C and increased the HDL-C content in MT-treated rats compared with the 
model group. These changes were dose dependent. MT treatment also 
significantly elevated the activity of SOD and GSHP-X, and decreased the serum 
levels of MDA compared with untreated hyperlipidemic rats, thereby increasing 
serum antioxidant capacity. In addition, MT reduced liver steatosis in 
hyperlipidemic rats. Overall, MT exerts considerable hypolipidemic and 
antioxidant properties.(10) 
 Surya et al .,(2016) evaluated the antihyperlipidemic activity of Ficus 
dalhousiae stem bark  methanolic extract (250 and 500 mg/kg b. wt.) in Triton 
WR-1339 and high fat diet-induced hyperlipidemic rats. F. dalhousiae extract 
significantly(P< 0.005) alter the serum TC, TG, LDL-C and HDL-C levels to near 
normal in Triton WR-1339 and high fat diet-induced hyperlipidemic rats. The 
liver total cholesterol and triglycerides were also significantly reduced after 
treatment with 250 and 500 mg/kg of F. dalhousiae. The result of their study 
indicated that F. dalhousiae has a significant potential to use as a natural 
antihyperlipidemic agent.(11) 
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  Liu et al., (2016) investigated the hypolipidemic effects of the aqueous 
leaf extract of Carmona microphylla (Lam.) G. Don. (CAE) in vitro and in vivo. 
The lipid-lowering effect of CAE was investigated in oleic acid induced steatosis 
in HepG2 liver cells, as well as in high-fat diet (HFD)- and triton WR-1339 (TRI)-
induced hyperlipidemic mice. The levels of intracellular, serum and/or  
hepatic total cholesterol (TC); triglyceride (TG); lowdensity lipoprotein-
cholesterol (LDL-c); high density lipoprotein-cholesterol (HDL-c); hepatic 
superoxidedismutase (SOD) activity and malondialdehyde (MDA) were 
determined by oil-red O staining and appropriate kits. Treatment with CAE 
inhibited lipid accumulation in HepG2 cells and reduced the elevated levels of 
serum TC, TG and LDL-c as well as hepatic TC and TG in hyperlipidemic mice 
induced by HFD. CAE administration also significantly decreased arteriosclerosis 
index and LDL-c/HDL-c ratio, but improved oxidative status as revealed by 
increased hepatic SOD activity and decreased MDA level. The lipid ameliorating 
and antioxidative effects of CAE (600 mg/kg) were comparable to those of the 
standard lipid-lowering drug, simvastatin (5mg/kg). Their results suggested that C. 
microphylla aqueous extract (CAE) protects against hyperlipidemia induced by 
HFD in mice and may find therapeutic application in hyperlipidemic patients.(12) 
 Zhang et al., (2016) investigated the therapeutic effect and potential 
mechanism of the fruit of Ficus suspensa using streptozotocin (STZ)-induced 
diabetic mice. Crude methanol extract of F. suspensa fruit was fractionated with 
different solvents and the ethyl acetate fraction (EAF) was selected for in vivo 
studies based on the in vitro α-amylase and HMG-CoA reductase (3-hydroxy-3-
methyl-glutaryl coenzyme A) inhibiting activities. For in vivo study, diabetes 
mellitus was induced in mice with STZ. Diabetic mice were orally administrated 
with 50, 100 and 200 mg/kg body weight of EAF for 4 weeks. Mouse body 
weight, blood glucose, glucose tolerance, biochemical parameters and gene 
expression related to pancreas and liver function were analyzed after EAF 
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administration. After 4 weeks of EAF intervention, a significant decrease in blood 
glucose, triglyceride, creatinine total cholesterol, acid phosphatase, alkaline 
phosphatase, aspartate transaminase, alanine transaminase, and hepatic lipid 
(triglycerides and cholesterol) content as well as a significant increase in body 
weight, insulin secretion and glucose tolerance was observed in EAF treated 
diabetic mice. qRT-PCR analysis revealed that EAF antagonized STZ-induced 
alteration of the expression of rate-limiting enzymes (glucokinase and 
phosphorenolpyruvate carboxykinase) in liver and insulin secretion related genes 
insulin-1, insulin-2 and duodenal homeobox factor-1 in pancreas. The ethyl 
acetate extract of Forsythia suspense (Thunb.) Vahl fruit has potency to develop 
an anti-hyperglycemic and anti-hyperlipidemic agent for the treatment of diabetes 
mellitus via modulation of oxidative stress, the hepatic glucose metabolism and 
pancreatic insulin secretion.(13) 
 Adeneye and Crooks (2015) investigated the weight losing, 
antihyperlipidemic and cardioprotective effects of the alkaloid fraction of 
Hunteria umbellata   (H. umbellata) seed. Adult female Wistar rats (weight range: 
120-150 g) were randomly divided into 4 and 5 treatment groups in the normal 
and triton-induced hyperlipidemic models, respectively and were daily treated for 
14 d before they were humanely sacrificed under inhaled diethyl ether anesthesia. 
About 5 mL of whole blood was obtained by cardiac puncture from each treated 
rat, from which serum for lipids assay was subsequently separated. Tissue samples 
of livers of treated rats were harvested and processed for histopathological 
analysis. Overall, results of their study showed that repeated oral treatments with 
25 and 50mg/kg/day of alkaloid fraction of H.umbellata elicited weight losing, 
antihyperlipidemic and cardioprotective effects in triton WR-1339 induced 
hyperlipidemic rats that were mediated via de novo cholesterol biosynthesis 
inhibition.(14) 
 
 
 El-Tantawy et al., (2015) investigated the hypolipidemic effect of an 
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ethanolic extract from the roots and rhizomes of Panicum repens L.in rats 
suffering from high-cholesterol, diet induced hyperlipidemia, and the 
phytochemicals in the extract were analyzed. The extract was administered p.o.in 
doses of 250 mg/kg/day together with cholesterol at a dose of 100 mg/kg/day for 7 
weeks. The high-cholesterol diet caused a significant increase in total lipids, total 
cholesterol (TC), total triglycerides (TG), low-density lipoprotein cholesterol 
(LDL-C), and the atherogenic index, whereas the level of high-density lipoprotein 
cholesterol (HDL-C) was significantly decreased. Administration of the P. repens 
extract (p < 0.05) significantly reduced the rise of the serum levels of total lipids, 
TC, TG, and LDL-C, as well as the atherogenic index, whereas it significantly 
increased (p < 0.05) the level of HDL-C. HPLC analysis of the phenolics and 
flavonoids in the extract revealed the presence of gallic acid, chlorogenic acid, 
chicoric acid, primulic acid, rutin, apigenin-7-glucoside, and quercetin. In 
conclusion, the P. repens extract was found to possess hypolipidemic activity in 
high-fat, diet-induced hyperlipidemic rats.(15) 
 
 Rony et al., (2014) studied the hypolipidemic activity of Phellinus rimosus 
studied using tritonWR-1339 and high cholesterol diet (HCD) induced models. 
The triton induced elevated lipid profile was attenuated by P. rimosus or standard 
drug atorvastatin. Similarly, administration of P. rimosus along with HCD 
significantly decline serum triglyceride, total cholesterol, low-density lipoprotein, 
with elevating the high-density lipoprotein. Thiobarbituric acid reacting 
substances in heart and liver significantly decreased; whereas activity of 
enzymatic antioxidants and level of reduced glutathione were significantly 
increased. In both models, P.rimosus extract showed a significant ameliorative 
effect on the elevated atherogenic index as well as LDL/HDL-C ratio. The 
hypolipidemic activity of P. rimosus can be ascribed to its inhibitory effect on the 
liver HMG CoA reductase activity. The results suggest the possible therapeutic 
potential of this fungus as hypolipidemic agent.(16) 
 Thirumalai et al., (2014) evaluated the hypolipidemic effect of Piper 
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betel (P. betel) in high fat diet induced hyperlipidemia rat. The methanol leaf 
extract was tested for hypolipidemic effect in the albino rats at the selected 
optimum dosage of 250 mg/kg body weight orally.  In negative control animals, 
the activity levels of serum total cholesterol (TC), triglycerides (TG), low density 
lipoprotein (LDL) and very low density lipoprotein-cholesterol (VLDL) were 
significantly enhanced when compared to that of normal rat. It could be said that 
the methanolic leaf extract of P. betel exhibited a significant hypolipidemic 
effect.(17) 
 
 Irudayaraj et al., (2013) evaluated the in vitro antioxidant and 
antihyperlipidemic activity of Toddalia asiatica (L) Lam. leaves in Triton WR-
1339 and high fat diet-induced hyperlipidemic rats. In in vitro studies T. asiatica 
leaves ethyl acetate extract showed very good scavenging activity on  
2,2-diphenyl-picrylhydrazyl (DPPH) (IC50 605.34 ± 2.62 lg/ml), hydroxyl (IC50 
694.37 ± 2.12 lg/ml) and nitric oxide (IC50 897.83 ± 1.48 lg/ml) radicals, as well 
as high reducing power. In Triton WR-1339 induced hyperlipidemic rats, oral 
treatment with T. asiatica leaves ethyl acetate extract produced a significant 
 (P< 0.005) decrease in the levels of serum total cholesterol (TC), triglycerides 
(TG), low-density lipoprotein-cholesterol (LDL-C), and significant increase in 
high-density lipoprotein cholesterol (HDL-C) in comparison with hexane and 
methanol extracts. In high fat diet-fed hyperlipidemic rats, the ethyl acetate extract 
(200 and 400 mg/kg) significantly altered the plasma and liver lipids levels to near 
normal.(18) 
 Thirumalaisamy et al., (2013) evaluated the the effect of the ethyl-acetate 
fraction of an ethanolic extract from Streospermum suaveolens on lipid 
metabolism in streptozotocin (STZ)-induced diabetic rats. The present study 
demonstrated that the ethyl-acetate fraction of Stereospermum suaveolens exhibits 
a potent antihyperlipidemic activity in hyperglycemic rats and suggests that the 
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plant may have therapeutic value in treating the diabetic complication of 
hyperlipidemia.(19)  
 Khanna et al.,(2002) studied the lipid lowering activity (LLA) of 
Phyllanthus niruri  in triton and cholesterol fed hyperlipemic rats. Serum lipids 
were lowered by P. niruri extract orally fed (250 mg/kg b.w.) to the triton WR-
1339 induced hyperlipemic rats. Chronic feeding of this drugs (100 mg/kg b.w.) in 
animals simultaneously fed with cholesterol (25 mg/kg b.w.) for 30 days caused 
lowering in the lipids and apoprotein levels of VLDL and LDL in experimental 
animals. The LLA of this drug is mediated through inhibition of hepatic 
cholesterol biosynthesis, increased faecal bile acids excretion and enhanced 
plasma lecithin: cholesterol acyltransferase activity.(20) 
 Veeramani et al., (2012) investigated the antihyperlipidemic effect of 
crude ethanolic extract of Melothria maderaspatana leaf (CEEM) on 
deoxycorticosterone acetate (DOCA)-salt hypertensive rats. In DOCA-salt 
hypertensive rats, the level of plasma and tissues of total cholesterol (TC), 
triglycerides (TG), free fatty acids (FFA) and phospholipids (PL) significantly 
increased and administration of CEEM significantly reduced these parameters 
towards normality. Further, the levels of low density lipoprotein-cholesterol 
(LDL-C) and very low density lipoprotein-cholesterol (VLDL-C) significantly 
increased while high density lipoprotein cholesterol (HDL-C) decreased in 
hypertensive rats and administration of CEEM brought these parameters to 
normality which proved their antihyperlipidemic action. Histopathology of liver, 
kidney and heart on DOCA-salt induced rats treated with CEEM showed reduced 
the damages towards normal histology. Their findings provided evidence that 
CEEM was found to be protecting the liver, kidney and heart against DOCA-salt 
administration and the protective effect could attribute to its antihyperlipidemic 
activities.(21) 
 Umamaheswari et al .,(2012) evaluated the in vitro anticataract and 
antioxidant activities of ethanolic seed extract of Abrus precatorius Linn. 
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(Fabaceae) against calcium-induced cataractogenesis using goat lenses. 
Transparent isolated goat lens were incubated in artificial aqueous humor and 
divided into seven experimental groups. The extracts at a dose of 100 μg/ml and 
200 μg/ml were incubated simultaneously with calcium chloride (10 mM) for a 
period of 16 h. Vitamin E (100 μg/ml) was used as the standard drug. At the end 
of the incubation, levels of various biochemical parameters such as protein 
content, malondialdehyde (MDA), lipid hydroperoxides (LH), Cu2+-induced 
lipoprotein diene formation, Ca2+ATPase and enzymatic antioxidants like 
catalase (CAT), glutathione peroxidase (GPx), superoxide dismutase (SOD), 
glutathione reductase (GSSH) and non-enzymatic antioxidant like reduced 
glutathione(GSH) were measured in the lens homogenate. Incubation with 
calcium produced a mature cataract and there was a significant increase in LH and 
MDA and a decrease in protein content, Ca2+ATPase, Cu2+-induced lipoprotein 
diene formation and enzymatic and non-enzymatic antioxidants when compared to 
normal control. Their results indicated that simultaneous incubation of the plant 
extracts prevented the preoxidative damage caused by calcium, which is 
evidenced from the improved antioxidant potential. The ethanolic seeds extract of 
Abrus precatorius protected the lens against calcium-induced oxidative damage 
which might be helpful in delaying the progression of cataract.(22) 
 Kamesh et al.,(2012) explored the effect of alcoholic extract of Bacopa 
monniera (AEBM) on high cholesterol diet-induced rats. AEBM treatment 
significantly decreased the levels of TC, TG, PL, LDL, VLDL, atherogenic index, 
LDL/HDL ratio, and TC/HDL ratio but significantly increased the level of HDL 
when compared to HCD induced rats. Activities on liver antioxidant status (SOD, 
CAT, GPx, GR, GST) were significantly raised with concomitant reduction in the 
level of LPO were obtained in AEBM treated rats when compared to HCD rats. 
Treatment with AEBM significantly lowered the activity of SGOT, LDH and 
CPK. Histopathology of aorta of cholesterol fed rat showed intimal thickening and 
foam cell deposition were noted. Their results suggested that AEBM extended 
 Review of Literature 
 
 
 
In vitro  Cholesterol Esterase Inhibitory Activity and In vivo 
 Anti-Hyperlipidimic  Activity of Anisomeles malabarica 49 
protection against various biochemical changes and aortic pathology in 
hypercholesterolemic rats. Thus the plant may therefore be useful for therapeutic 
treatment of clinical conditions associated hypercholesterolemia.(23) 
 Hariri and Thibault (2010) described the history of using high-fat diet to 
induce obesity in animals, aims to clarify the consequences of changing the 
amount and type of dietary fats on weight gain, body composition and adipose 
tissue cellularity, and explores the contribution of genetics and sex, as well as the 
biochemical basis and the roles of hormones such as leptin, insulin and ghrelin in 
animal models of dietary obesity. The major factors that contribute to dietary 
obesity – hyperphagia, energy density and post-ingestive effects of the dietary fat 
– are discussed. Other factors that affect dietary obesity including feeding 
rhythmicity, social factors and stress are highlighted. Finally, they commented on 
the reversibility of high-fat diet-induced obesity.(24) 
  
           Dhulasavant et al.,(2010) investigated the hypolipidemic effect of 
Cinnamomum tamala  leaves extracts in high cholesterol diet induced 
hyperlipidemia. Aqueous and ethanolic extracts of leaves of Cinnamomum tamala 
were administered in doses of 400mg/kg /day p.o. each for 10 days. Simultaneous 
administration of Cinnamomum tamala leaves extracts significantly (p<0.001) 
prevent the rise in serum levels of total cholesterol, triglyceride, LDL-C,VLDL-C 
and Atherogenic index whereas significant (p<0.01) increases in the level of 
HDL-C.(25) 
 
 
                 Ghule et al .,(2009) investigated the effect of methanolic extract from 
Lagenaria siceraria in experimentally induced hyperlipidemia in rats.  Methanolic 
extract of Lagenaria siceraria fruits (LSFE) (100, 200 and 300 mg/kg; p.o.) was 
administered to the high fat-diet-induced hyperlipidemic rats for 30 days to 
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evaluate its antihyperlipidemic activity. Atorvastatin (10 mg/kg; p.o.) was used as 
a standard drug. At the 30th day, most significant reduction in lipid levels in the 
LSFE treated rats as compared to the rats fed with high-fat diet at the 0th day 
were: total cholesterol , low-density lipoprotein cholesterol, triglyceride, very low-
density lipoprotein cholesterol (P < 0.0001). Conversely, high-density lipoprotein 
cholesterol levels were significantly (P < 0.0001) increased. The increase in 
weight in rats administered with LSFE was less when compared to rats fed with 
high-fat diet. Moreover, LSFE also exhibited significant increase in excretion of 
bile acids. Their results demonstrated that the LSFE has a definite 
antihyperlipidemic potential. There is also a valid scientific basis for consuming it 
in the treatment of coronary artery diseases in India.(26) 
 
              Kumar et al.,(2008) studied the hypolipidemic action of Anthocephalus 
indicus (family, Rubiaceae) fruit extract has been studied in hyperlipidemic rats 
fed a triton- and cholesterol-rich high-fat diet. In triton WR-1339-induced 
hyperlipidemic rats, feeding with the fruit extract (500 mg/kg b.w.) exerted a 
lipid-lowering effect as assessed by reversal of plasma levels of total cholesterol, 
phospholipids, and triglyceride following reactivation of the post-heparin lipolytic 
activity. In another model, chronic feeding of this natural product (500 mg/kg, 
b.w.) to animals simultaneously fed a high-fat diet for 30 days caused lowering of 
lipid levels in plasma and liver accompanied with stimulation of hepatic lipolytic 
activity. The hypolipidemic activity of Anthocephalus indicus fruit extract was 
compared with guggulipid, a known lipid-lowering drug, in both models.(27) 
 
              Kumari et al .,(2006) tested the total alcoholic extract of Eclipta 
prostrata for antihyperlipidemic potential, which exhibited a dose-dependent 
activity in albino rats when compared to standard drugs. The activity was assessed 
by studying the lipid profiles of serum, liver and heart of the control and drug-
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treated animals. Their results lend support to the traditional use of Eclipta 
prostrata in the treatment of hyperlipidemia.(28) 
 
               Galati et al ., (1999) evaluated the effects of prolonged administration of 
a lyophilized stem decoction of Salvadora persica in diet-induced rat 
hypercholesterolemia. The preparation was administered for 15 and 30 days (by 
gavage at a dose of 500 mg/kg in an aqueous vehicle in a volume of 0.5 ml/100 g 
b.w.). Cholesterol, HDL, LDL and triglyceride plasma levels were assayed. Their 
results showed that the S.persica decoction significantly lowered cholesterol and 
LDL plasma levels in rats, proving to be more active at 30days of treatment. The 
systemic administration of Triton results in a rise in plasma cholesterol and 
triglyceride levels. The results obtained show that S.persica decoction was 
inactive at 18 hr after treatment, whereas at 27 hr, it was able to reduce cholesterol 
and LDL plasma levels. In all experiments HDL and triglycerides were 
unchanged.(29) 
LITERATURE RELATED TO PLANT 
              Sheikh et al.,(2016) evaluated the different solvent plant extracts and 
essential oil of Anisomeles malabarica  leaves and flowers for in vitro anti-
inflammatory and anti-oxidant activity using different assay method. The in vitro 
anti-inflammatory activities were analyzed by; Heat Induced Hemolytic and 
Protein Denaturation method using Diclofenac sodium as a standard. Anti-oxidant 
potencies were ascertained by 1, 1-diphenyl-2-picrylhydrazyl (DPPH) radical 
scavenging and Iron chelating methods. Ascorbic acid was used as a standard. The 
percentage inhibition and stabilization values for anti-inflammatory and 
scavenging and chelation values for anti-oxidant were obtained and tabulated. The 
result clearly indicates that the methanolic extracts of both flower and leave of the 
study species shows effective anti-inflammatory and anti-oxidant properties. This 
scavenging free radical capacity can be used as a good anti-oxidizing agent in 
various fields of medicine, food industry etc.(30) 
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            Packialakshmi and Periyakkal (2015)  tested Anisomeles malabarica 
plant leaves for their FTIR spectroscopic studies revealed different characteristic 
peak values with various compounds in the leaf. The FTIR method was performed 
by spectrophotometer system, which was used to detect the characteristic peak 
values and their functional group of Amines, Ether, Mono substituted, Alkenes 
and nitro compounds. Leaf extracts of Anisomeles malabarica were evaluated for 
phytochemical screening to identify the active compounds.(31) 
 
            Unpaprom et al., (2015) assessed the role of larvicidal activities of 
methanolic leaf and inflorescence extract of Anisomeles malabarica (L.) against 
malarial vector Anopheles stephensi Liston (Insecta: Diptera : Culicidae). The 
larvicidal activity was assayed against the mosquito species at various 
concentrations ranging from (20 to 100 ppm) under the laboratory conditions. The 
LC50 and LC90 value of the methanolic leaf and inflorescence extract of 
Anisomeles malabarica (L.) was determined by Probit analysis. The percentage of 
mortality of Anopheles stephensi after the treatment of Anisomeles malabarica on 
I to IV instar larvae from 20,40,60,80 to100 ppm. The LC50 and LC90 values 
were represented as follows: LC50 value of I instar was 50.24%, II instar was 
54.70%, III instar was 59.03% and IV instar was 64.33%, respectively. LC90 
value of I instar 106.99%, II instar was 113.33%, III instar was 118.04% and IV 
instar was 119.94%, respectively. The present results suggest that the effective 
Anisomeles malabarica leaf and inflorescence crude extracts have potential to be 
used as an ideal eco-friendly approach for the control of mosquito vectors.(32) 
           Nilofer and Packialakshmi (2014) evaluated the aqueous leaf, flower, 
stem and boiled leaf extracts of Anisomeles malabarica for antibacterial screening 
by disc diffusion methods along with their phytochemical screening. The 
Anisomeles malabarica extracts are sensitive to five pathogenic organisms such as 
Staphylococcus aureus, Staphylococcus epidermis, E.coli, Pseudomonas 
aeroginosa and Bacillus substilis except Proteus vulgaris by disc diffusion 
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methods. They carried out the phytochemical screening to identify the active 
compounds in the extracts.(33) 
 
            Packialakshmi and Nilofer (2014) reported the antibacterial activity of 
Anisomeles malabarica. Sequential extraction was carried out by using solvent 
such as ethanol, methanol, petroleum ether and aqueous extract from the leaf and 
boiled leaf of plant were investigated for preliminary antibacterial property against 
some pathogenic bacteria. In polar studies the maximum zone of inhibition were 
found in Staphylococcus aureus. In non-polar studies the maximum zone of 
inhibition were found in Pseudomonas aeruginosa. All these findings have 
confirmed the uses of this plant in a broad spectrum to treat several bacterial 
infections. Their results showed good antibacterial activity and it could play an 
important role in herbal formulations for the treatment of infectious diseases.(34)  
 
             Vinod et al.,(2014) investigated the preliminary bioactive phytochemicals 
present in the leaves extracts obtained by analytical standard hexane and ethanol 
solvents. The phytochemicals were analysed such as alkaloids, flavonoids, 
saponins, tannins and terpenoids from both the leaves extracts. Their study also 
extends to evaluate the antimicrobial activity of Anisomeles malabarica leaves 
extracts. The in vitro antimicrobial activity was performed by agar well diffusion 
method against the clinically important multi drug resistant bacterial strains viz., 
Staphylococcus aureus (NCIM 2492), Bacillus subtillis (NCIM 2439) and 
Klebsiella pneumoniae (NCIM 2719) with the concentration of extracts ranged 
from 25 to 75μL. It has shown the concentration dependent antimicrobial activity 
(MIC). Their study shows the powerful antimicrobial activity against 
Staphylococcus aureus and Klebsiella pneumoniae bacterial strains with 
maximum inhibitory zone compared with standard antibiotic drug tetracycline.(35) 
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             Ramaraj and Unpaprom (2013) evaluated the larvicidal and pupicidal 
activities of crude methanol extract of Anisomeles malabarica. The extract was 
assayed for their toxicity against the important vector mosquitoes Anopheles 
stephensi. The plant extract showed larvicidal effects after 24 h of exposure; 
however, the highest larval and pupal mortality was found in the methanol extract 
of Anisomeles malabarica against the first to fourth instars larvae and pupae. 
Their result suggested that the plant extract have the potential to be used as an 
ideal eco-friendly approach for the control of mosquito vector. This paper gives a 
bird’s eye view mainly on the biological activities, pharmacological actions, and 
plausible medicinal applications of Anisomeles malabarica. Different aspects of 
Anisomeles malabarica medicinal values are briefly demonstrated, such as 
potential anti-allergic, anti-anaphylactic, anti-bacterial, anticancer, anti-
carcinogenic, anti-inflammatory, antiepileptic potential, antifertility, anti-pyretic 
activity and antispasmodic. (36) 
 
          Subramanian and Muthukrishnan(2013) investigated the antibacterial 
properties of various extracts of Anisomeles malabarica (L) against both clinical 
and laboratory isolates of bacteria using the disc diffusion method. Aqueous 
extracts (10 mm zone diameter of inhibition, MIC 10μg/mL) demonstrated the 
highest activity, followed by Ethanolic extract (8 mm zone diameter of inhibition, 
MIC 20μg/mL) methanolic extract demonstrated the least activity against the test 
bacteria (4 mm zone diameter of inhibition, MIC 40 μg/mL). Generally the 
antibacterial activities of Anisomeles malabarica are comparable to that of 
standard oflaxcin to a certain extent. Finally, these results suggested that 
Anisomeles malabarica (L) can be used to source antibiotic substances for 
possible treatment of bacterial infections and for the development of new drugs.(37) 
 
 Kavitha et al ., (2012) evaluated the in vitro antibacterial activity of leaf 
extracts of Anisomeles malabarica against E.coli, S.aureus, P.mirabilis, 
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P.aeruginosa, K.pneumonia. The preliminary phytochemmical analysis of both 
Ethanolic and Diethyl ether extracts revealed the presence of alkaloids, 
flavonoids, tannins, safonins, and glycosides. It was found that the ethanolic 
extract exhibited a maximum antibacterial activity at 200μg/ml and produced 
25mm zone of inhibition against S.aureus where as Diethyl ether extract produced 
30mm zone of inhibition in the same concentration. Their results provide 
justification for the use of A. malabarica to treat various infectious diseases.(38) 
 Choudhary et al .,(2011) isolated and evaluated the anti-epileptic 
potential of fractions from the ethyl acetate extract (EAE) of Anisomeles 
malabarica leaves.Thus, it may be concluded that the flavonoids fraction of the 
EA extract of Anisomeles malabarica leaves has antiepileptic potential against 
both MES and PTZ convulsion models. Acute treatment (25 and 50 mg/kg, i.p.) is 
associated with neurotoxic activity. Whereas, chronic treatment (6.25 and 12.5 
mg/kg, i.p., 1 week) also shown significant antiepileptic effect without causing 
neurotoxic side effects. However, further research is in progress to determine the 
component(s) of the flavonoids fraction of Anisomeles malabarica involved and 
their mechanism of action in bringing about the desirable anti-epileptic effect.(39) 
  
            Vijayalakshmi and Ranganadhan(2011) tested the ethyl acetate extract 
of leaves from Anisomeles malabarica for in vitro antioxidant using various free 
radical scavenging assays. Free radical scavenging assays such as hydroxyl, 
superoxide anion radicals, 2,2-diphenyl-1-picryl hydrazyl (DPPH) and 2,2’-
azinobis-(3-ethyl-enzothiazoline-6-sulfonic acid) (ABTS) radical scavenging 
assays were performed. It was observed that the extract effectively scavenged 
hydroxyl and superoxide anion radicals. It also scavenges DPPH and ABTS 
radicals. All the concentrations of leaf extract showed free radical scavenging and 
antioxidant power and the preventive effects were in a dose-dependent manner. 
Those various antioxidant activities were compared to standard antioxidants such 
as ascorbic acid, butylated hydroxytoluene (BHT) and á-tocopherol. Thus, the 
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results obtained in their present study indicated that  A. malabarica extract could 
be considered as a potential source of natural antioxidants.(40) 
 Singh et al.,(2009) investigated the anticonvulsant potential of chloroform, 
ethyl acetate and methanol extracts of leaves of Anisomeles malabarica against 
pentylenetetrazole (PTZ) and maximal electroshock (MES) induced convulsions. 
All the three extracts were administered (i.e. 100, 200, 400 mg/kg, p.o.) for 7 days 
and at the end of the treatment convulsions were induced experimentally. 
Diazepam and phenytoin (1 mg/kg, i.p. and 25 mg/kg, i.p., respectively) were 
used as reference anticonvulsant drugs against experimentally induced 
convulsions. High doses (400mg/kg, p.o.) of chloroform and ethyl acetate extracts 
both significantly decreased the extent of MES- and PTZ-induced convulsions. On 
the other hand, ethyl acetate extract at lowest and medium selected doses (i.e. 100 
mg/kg, p.o. and 200 mg/kg, p.o., respectively, for 7 days) had also significantly 
attenuated PTZ-induced convulsions. However, methanol extract at any of the 
doses used (i.e. 100, 200 and 400 mg/kg, p.o.) did not show any significant effect 
on PTZ- and MES-induced convulsions. None of the extracts at doses used in the 
present study have altered locomotor activity and motor coordination. Hence, it 
may be concluded that chloroform and ethyl acetate extracts of Anisomeles 
malabarica leaves are effective against PTZ- and MES induced-convulsions in 
rats.(41)                 
Objective of the Study 
 
 
 
In vitro Cholesterol Esterase Inhibitory Activity and In vivo 
 Anti-Hyperlipidemic  Activity of Anisomeles malabarica 57 
OBJECTIVE OF THE STUDY 
 Hyperlipidemia is a heterogeneous disorder characterized by an elevation 
in total cholesterol (TC), triglycerides (TG), very low density lipoprotein 
cholesterol (VLDL-C), low-density lipoprotein cholesterol (LDL-C), free fatty 
acids (FFA), and apolipoprotein B (apo B) levels, as well as reduced high-density 
lipoprotein cholesterol (HDL-C) levels. These disorders happen as a result of 
either metabolic disorders or dietary and lifestyle habits. Several studies have 
revealed that an decrease in HDL-C and increase in TC, LDL-C and TG are 
associated with an increase in the risk of ischemic heart diseases. Many drugs 
have been reported to possess hypolipidemic activity like  bile acid binding resins, 
statins, fibrates, niacin and cholesterol absorption inhibitors which are the 
common treatment for hyperlipidemia. However, severe side effects are associated 
with the use of these drug for lipid-lowering medications.(3) 
 Many natural compounds were reported as hypolipidemic agents such as 
polyphenolics, flavonoids, tannins, alkaloids, phytosterol, unsaturated fatty acids 
and dietary fibers.(7)  
            The main objective of this study was to evaluate the in vitro cholesterol 
esterase inhibitory activity and in vivo antihyperlipidemic activity of Anisomeles 
malabarica leaf extract. 
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PLAN OF WORK 
        The work involved the following steps, 
 Review of literature 
 Plant collection and authentication of the leaves of Anisomeles malabarica, 
 Preparation of cold the extract, 
 Phytochemical screening, 
 GC-MS analysis, 
 Cholesterol esterase inhibitory activity using in vitro methods, 
 Acute toxicity studies, 
 Antihyperlipidemic activity of Anisomeles malabarica using in vivo methods 
 in rat, 
 Determination of serum biochemical parameters, 
 Estimation of tissue protein and malondialdehyde in experimental animals. 
 Estimation of liver and heart enzymatic antioxidants like superoxide 
dismutase, catalase, glutathione peroxidase, glutathione reductase in 
experimental animals, 
 Estimation of liver and heart non-enzymatic antioxidants like reduced 
 glutathione, 
 Histopathological studies of the liver and heart tissues, 
 Tabulation, statistical analysis and thesis writing. 
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MATERIALS AND METHODS 
 
Experimental animals 
  Albino wistar rats of either sex weighing between 125-150 g were used 
for the study. The animals were housed in polypropylene cages inside a well-
ventilated room. The room temperature was maintained at 23±2˚C with a 12 h 
light / dark cycle. The animals were fed with commercial rat feed pellets and 
provided with drinking water ad libitum. All animal procedures have been 
approved by ethical committee in accordance with animal experimentation and 
care. 
Drugs and chemicals 
 Cholesterol Esterase and pNPB (P-nitro phenyl butyrate) were purchased 
from the Sigma Aldrich, USA. Acetonitrile, taurocholate were purchased from 
Loba chemicals, Mumbai. Gallic acid were purchased from HiMedia, Mumbai. 
High Fat Diet (HFD) food for rats were purchased from RSM Hitech Feeds, 
Namakkal. Atorvastatin is used as a standard drug were purchased from 
Medopharm, Chennai. Cholesterol, triglycerides, HDL, LDL, AST, ALP, ALT 
and LDH levels were determined using standard kits obtained from Agappe 
diagnostics Pvt., Ltd., Kerala. 
Instrument used 
 Digital balance (Sartorius Ltd, USA), UV (Jasco UV-spectometry), pH 
meter (Elico) and GC-MS.  
Plant material 
 The plant material consists of dried powdered leaves of Anisomeles 
malabarica L. belonging to the family Lamiaceae. 
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Plant collection and authentication 
 The leaves were collected near Dharapuram, dry region of Thirupur 
district, Tamil Nadu, India. The plant was  identified and authenticated by Dr. M. 
Palanisamy, scientist ‘D’-In-charge in Botanical Survey of India, T.N.A.U. 
Campus, Coimbatore, Tamil Nadu bearing the reference number 
BSI/SRC/5/23/2017/TECH.2814.  
 
Plant extraction  
 The leaves were separated and dried in shade under room temperature, 
powdered mechanically and sieved through No.20 mesh sieve. The finely 
powdered leaves were kept in an airtight container until the time of use.  
 
 In the cold maceration process, about 25 gm of the whole or coarsely 
powdered crude drug is placed in a stoppered container with the 70% ethanol and 
30% water and allowed to stand at room temperature for a period of at least 3 days 
with frequent agitation until the soluble matter has dissolved. On the fourth day 
the mixture is then strained, the marc is pressed, and the combined liquids are 
clarified by filtration or decantation after standing.  
 
Phytochemical screening 
 Chemical tests were carried out for the various fractions of Anisomeles 
malabarica for the presence of phytochemical constituents .(43) 
Test for alkaloids 
 To a little of plant leaves extract a few drops of Mayer’s test reagent was 
added. Formation of precipitate indicates presence of alkaloids. 
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Test for flavonoids 
 1ml of extract was taken and few drops of very dilute solution of ferric 
chloride were added. The color changed to pale green or red brown color which 
indicates the presence of flavonoids. 
Test for saponins  
 One ml extract and one ml alcohol diluted with 20 ml distilled water and 
shaken well for 15 minutes. The formation of 1cm layer of foam indicated the 
presence of saponins. 
Test for carbohydrates 
 Small amount of extract was dissolved separately in 5 ml distilled water 
and filtered. The filtrate was subjected to molisch’s test. Formation of reddish 
brown ring indicates the presence of carbohydrate. 
Test for tannins 
 To 5ml of extract solution, 1ml of lead acetate solution was added. 
Flocculent brown precipitate indicates the presence of tannins. 
Test for glycosides 
 A small portion of extract was hydrolyzed with hydrochloric acid for few 
hours on a water bath and the hydolysate was subjected to legal’s test to detect the 
presence of different glycosides. 
Legal’s test 
 To the hydrolysate 1ml of sodium nitroprusside solution was added and 
then it was made alkaline with sodium hydroxide solution. If the extract produced 
pink to red color, it indicates the presence of glycosides. 
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Test for fixed oils and fats 
 Few drops of 0.5N alcoholic potassium hydroxide were added to small 
quantity of various extracts along with a drop of phenolphthalein. The mixture 
was heated on a water bath for 1-2 hrs. Formation of soaps or partial 
neutralization of alkali indicates the presence of fixed oils and fats. 
Test for phenols (ferric chloride test) 
 A fraction of the extract was treated with aqueous 5% ferric chloride and 
observed for formation of deep blue or black color. 
Test for gums and mucilage 
 About 10ml of extract was added to 25ml of absolute alcohol with stirring 
and filtered. The precipitate was dried in air and examined for its swelling 
properties and for the presence of carbohydrates. 
Test for amino acids and proteins (1% Ninhydrin solution in acetone) 
 2ml of filtrate was treated with 2-5 drops of Ninhydrin solution placed in a 
boiling water bath for 1-2 minutes and observed for the formation of purple color. 
Gas Chromatography -Mass Spectroscopy Analysis 
Derivatization procedure: (44) 
 Two procedures were followed. For the crude ethanol ether and ethanol 
extracts, a small amount of concentrated sample was taken in a separating funnel 
and shaken by adding water and ethyl acetate in the ratio of 1:4. The upper layer 
was collected and concentrated in rotary evaporator to about 1.5 ml. Added 100μl 
N, O-Bis(trimethylsilyl) trifluoroacetamide and trimethyl chlorosilane 
(BSTFA+TMCS) and 20μl pyridine and heated at 60°C for 30 minutes. 
Materials & Methods 
 
 
 
In vitro Cholesterol Esterase Inhibitory Activity and In vivo  
 Anti-Hyperlipidemic  Activity of Anisomeles malabarica 63 
 For the layers which are separated from the crude extracts, a small amount 
of extract was taken and evaporated out totally. To this added acetonitrile and 
filtered into a conical flask. To the filtrate added 50μl BSTFA+TMCS and heated 
at 60°C in a water bath for 30 minutes. Filtered using 0.45μ membrane filter to a 
vial. 
GC-MS Analysis:  
 GC-MS analysis was carried out on a Perkin Elmer Turbo Mass 
Spectrophotometer (Norwalk, CTO6859, and USA) which includes a Perkin 
Elmer Auto sampler XLGC. The column used was Perkin Elmer Elite - 5 capillary 
column measuring 30m × 0.25mm with a film thickness of 0.25mm composed of 
95% Dimethyl polysiloxane. The carrier gas used was Helium at a flow rate of 
0.5ml/min. 1μl sample injection volume was utilized. The inlet temperature was 
maintained as 250°C. The oven temperature was programmed initially at 110°C 
for 4 min, then an increase to 240°C. And then programmed to increase to 280°C 
at a rate of 20°C ending with a 5 min. Total run time was 90 min. The MS transfer 
line was maintained at a temperature of 200°C. The source temperature was 
maintained at 180°C. GCMS was analyzed using electron impact ionization at 
70eV and data was evaluated using total ion count (TIC) for compound 
identification and quantification. The spectrums of the components were 
compared with the database of spectrum of known components stored in the GC-
MS library. Measurement of peak areas and data processing were carried out by 
Turbo-Mass-OCPTVS-Demo SPL software.(44) 
In vitro Cholesterol esterase inhibitory activity: 
 Enzyme inhibition assay is performed in presence of sodium taurocholate 
with p-nitrophenyl butyrate as chromogenic substrate.(45) Hydrolysis is performed 
in the presence of high enzyme concentration and products are identified 
spectrophotometrically. Assay buffer is sodium phosphate buffer (pH-7.0) which 
is made by adding 100 mM sodium phosphate with 100mM Nacl in deionised 
water. 
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        Stock solution of cholesterol esterase (19.5 ng/mL) and taurocholate (12mM) 
were prepared by using (100mM) sodium phosphate buffer of pH-7.0. Stock 
solution of pNPB (200μM), flavonoid compounds and standard of different 
concentrations (10-320μg/mL) are prepared by using acetronitrile (6%). A final 
volume of 1 ml is taken into a cuvette containing 430μL of assay buffer, 500μL of 
taurocholate solution, 40μL of acetonitrile 10μL of pNPB solution and 10μL of 
flavonoid solution are added and thoroughly mixed. Incubate for 2 minutes at 
25⁰ C, the reaction is initiated by adding 10μL of enzyme solution. The 
absorbance is measured at 405 nm against a blank. 
  
 Percentage inhibition is calculated by using formula, 
                                                                                                                                                                 
Cholesterol inhibition % I =  100 
inhibitorithout activity w Enzyme
inhibitor]ith activity w enzyme-[1 
x  
 Uninhibited enzyme activity is determined by acetonitrile instead of the 
inhibitor solution. Control absorbance is measured by adding 100mM sodium 
phosphate pH 7, instead of enzyme. Gallic acid is used as the reference 
standard.(45) 
Acute toxicity study of AMLE 
 Acute oral toxicity testing was carried out in accordance with the OECD 
guideline 420 Acute Oral Toxicity – Fixed Dose Procedure method (OECD, 
2002).  
 
Procedure  
 The acute toxicity study was done by two steps - Sighting study and  
Main study.  
 The purpose of the sighting study is to allow selection of the appropriate 
starting dose for the main study.  
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 Sighting study was conducted using one animal and main study using five 
animals, in which one animal is taken from the sighting study. Healthy adult 
female (generally slightly more sensitive than male) Albino wistar rats weighing 
between 220±20%g body weight were procured and kept in cages under ambient 
temperature (22±3°C) with 12 h light/dark cycle. The animals were randomly 
selected, marked and kept in their cages for 5 days prior to dosing for 
acclimatization to laboratory conditions. An animal was fasted over-night but 
water provided ad libitum and received a single dose (2000mg/kg, body weight, 
p.o.) of Anisomeles malabarica leaf Extract. After the administration of the 
extract, food was withheld for further 3-4h.  
 
 Animals were observed individually at least once during the first 30 min 
after dosing, periodically during the first 24h (with special attention during the 
first 4 h) and daily thereafter for a period of 14 days. Once daily cage side 
observations included changes in skin and fur, eyes and mucous membrane 
(nasal), and also respiratory rate, circulatory (heart rate and blood pressure), 
autonomic(salivation, lacrimation, perspiration, piloerection, urinary incontinence 
and defecation) and central nervous system (drowsiness, gait, tremors and 
convulsions) changes. 
  
 If the animal dosed with 2000mg/kg b.w. during the sighting study 
survives and remains so without any toxic manifestations then the same dose is 
selected for the main study. The main study was done in 4 animals other than that 
taken for the sighting study (a total of 5 animals). The procedure of the main study 
is similar to that of the sighting study. 
Table 5:  Design of acute toxicity studies 
Study involved Dose (mg/kg) No. of animals 
 5 1 
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Sighting study 
50 1 
300 1 
2000 1 
Main study 2000 5 
 
Selection of dose of the extract  
 LD50 was done as per OECD guidelines for fixing the dose for biological 
evaluation. The LD50 0f the fractions as per OECD guidelines falls under category 
4 values with no signs of acute toxicity at doses of 2000 mg/kg. The biological 
evaluation of the fractions was carried out at a dose of 200 mg/kg body weight. 
High fat diet fed rats of hypercholestremia in rats 
 Rat was fed with two dietary regimes such as Normal Pellet Diet (NPD) 
and High fat Diet (HFD). The rat was feeding either NPD or HFD ad libitum, 
respectively, for the period of  50 days. 
Composition of High Fat Diet (25 kg) 
 Maize :  5 kg 
 Soya meal :  5 kg 
 Coconut cake : 3 kg 
 Rice Polish :  2 kg 
 Groundnut cake :  5 kg 
 Tallow (Animal Fat) :  5 kg 
Experimental Design: 
 Healthy male or female Albino wistar strain weighing (125-150) g were 
used for the present study. The animals were housed in large spacious cages. Food 
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and water were given ad libitum. The animal house was ventilated with a 12 h 
light/dark cycle, throughout the experimental period. Rats were allowed to adapt 
to their environment condition for at least 10 days before the initiation of 
experiment.(46) 
 The rats were randomly divided into six groups of six rats each.  
Group I:   
 Control rats fed with normal diet for 50 days.  
Group II:  
 Rats fed with hypercholesterolemic diet (HCD) for 50 days.  
Group III:  
 Rats fed with HCD for 50 days + administrated with low dose of plant 
extract (100mg/kg, body weight/day orally) for last 35 days. 
Group IV:  
 Rats fed with HCD for 50 days + administrated with High dose of plant 
extract (200mg/kg, body weight/day orally) for last 35 days.   
Group V:  
 Rats fed with normal diet for 50 days + administrated with plant extract 
(200 mg/kg, body weight/day orally) for last 35 days. 
Group VI:  
 Rats fed with HCD for 50 days+ administered with standard drug (10 mg 
kg-1 body weight/day orally) for last 35 days. 
Measurement of Body weight, Food intake and Water Consumption 
         In addition, the food intake and water consumption of rats in all the groups 
were noted down. 
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Blood Collection: 
  At the end of the experimental period (50 days), blood was collected by 
retro-orbital puncture under mild ether anaesthesia. The blood was allowed to clot 
for approximately 1 hour at room temperature and then centrifuged at 5000 rpm 
for 10 min to obtain the serum. The levels of serum cholesterol, triglycerides, high 
density lipoprotein, low density lipoprotein, very low density lipoprotein, 
aspartate transaminase, alanine transaminase, alkaline phosphatase and lactate 
dehydrogenase, were determined using a semi-autoanalyser.(47) 
Serum parameters  
1. Alkaline phosphatase (ALP) 
2. Aspartate transaminase (AST) 
3. Alanine transaminase (ALT)  
4. Lactate dehydrogenase (LDH)   
5. High density Lipoprotein (HDL) 
6. Low density Lipoprotein(LDL) 
7. Very low density lipoprotein.(VLDL) 
8. Triglycerides (TG) 
9. Total cholesterol (TC) 
 
 
 
 
 
1. Alkaline phosphatase 
Principle 
 Kinetic determination of ALP according to the following reaction  
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  Para-nitrophenyl phosphate + H2O ALP    p-nitrophenol + Inorganic phosphate 
 
  ALP is widely distributed throughout the body, but clinically important 
one for diagnostic reasons are in bone, liver, placenta and intestine.  
 
Reagent preparation  
 Mix four volumes of reagent 1 (R1), which contains diethanolamine buffer 
(pH 10.2) 125 mmol/L, magnesium chloride 0.625 mmol/L with one volume of 
reagent 2 (R2) contains P-Nitro phenyl phosphate 50 mmol/L. This working 
reagent is stable for 30 days at 2-8°C. 
 
Procedure  
 To 20 µl of sample, 1 ml of working reagent was added. Mix and incubate 
at 37°C for one minute. Measure the change in absorbance per minute during 3 
minutes at 405nm.  
 
Aspartate transaminase 
Principle  
 Kinetic determination of aspartate aminotransferase (AST) based upon the 
following reaction. 
L-Aspartate + alpha-ketoglutarate    AST      Oxaloacetate + L-Glutamate 
                                                   MDH      
Oxaloacetate + NADH + H+     ------- > L-Malate + NAD+ 
MDH: Malate dehydrogenase 
 
Reagent preparation 
 Mix four volume of reagent 1 (R1) contains tris buffer (pH 7.8) 88 
mmol/L, L-aspartate 260 mmol/L, LDH>1500 U/L, MDH>900 U/L with one 
volume of reagent 2 (R2) contains alpha-ketoglutarate 12 mmol/L, NADH-0.24 
mmol/L. This working reagent is stable for 30 days at 2-8°C. 
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Procedure  
 To 100 µl of sample, 1 ml of working reagent was added. Mix and 
incubate at 37°C for one minute. Measure the change in absorbance per minute 
during 3 minutes at 340nm. 
Alanine transaminase 
Principle  
 Kinetic determination of Alanine transaminase (ALT) according to the 
following reaction.  
                                                              MDH 
 L-Alanine + alpha-ketoglutarate ------> Pyruvate + L-Glutamate 
  
 Pyruvate + NADH + H+        -------> L-Lactate + NAD+  
 LDH- Lactate dehydrogenase 
Reagent preparation 
 Mix four volume of reagent 1 (R1) contains tris buffer (pH 7.5) 110 
mmol/L, L-alanine 600 mmol/L, LDH>1500 U/L, with one volume of reagent 2 
(R2) contains alpha-ketoglutarate 16 mmol/L, NADH-0.24 mmol/L. This working 
reagent is stable for 30 days at 2-8°C. 
 
 
 
Procedure  
 To 100 µl of sample, 1 ml of working reagent was added. Mix and 
incubate at 37°C for one minute. Measure the change in absorbance per minute 
during 3 minutes at 340nm. 
 
LDH 
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Lactate dehydrogenase 
Principle  
 Kinetic determination of lactate dehydrogenase according to the following 
reaction.  
 
Pyruvate + NADH + H+        -------> L-Lactate + NAD+  
 
Reagent preparation 
 Mix four volume of reagent 1 (R1) contains tris buffer (pH 7.4) 80 
mmol/L, pyruvate 1.6 mmol/L, sodium chloride 200 mmol/L with one volume of 
reagent 2 (R2) contains NADH- 240 mmol/L. This working reagent is stable for 
21 days at 2-8°C. 
Procedure  
 To 10 µl of sample, 1 ml of working reagent was added. Mix and incubate 
at 37°C for one minute. Measure the change in absorbance per minute during 3 
minutes at 340nm. 
These parameters were determined using standard kits obtained from 
Agappe Diagnostics, Cochin, India using a Semi Auto-analyser (Mispa Viva, 
Mumbai, India).   
 
 
 
Triglycerides  
Principle: Enzymatic determination of triglycerides;  
 TGL reacting with water in the presence of lipoprotein lipase to gives 
 Glycerol and Fatty acid.  
LDH 
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 Glycerol is reacting with ATP in the presence of glycerol kinase to gives 
 Glycerol -3- phosphate and ADP. 
 Glycerol -3- phosphate reacting with 2 molecules of oxygen in the 
presence of Glycerol -3- phosphate oxidase gives dihydroxyacetophenone 
and 1 molecule of hydrogen peroxide. 
 2 molecules of hydrogen peroxide reacting with 4- aminoantipyrine and 
 TOPS gives violet coloured complex. 
Procedure:  
 Mix the triglyceride reagent (pipes buffer-5mmol/L, TOPS-5.3MMOL/L, 
Potassium ferrocyanate-10mmol/L, Magnsium salt- 17mmol, 4- aminoantipyrine-
0.8mmol/L, ATP-3.15mmol/L, lipoprotein lipase >1800 U/L, Glycerol-3-
phosphate oxidase >3500 U/L, Peroxidase >450) with triglycerides standard 
concentration- 200mg/dL .Read the initial absorbance at 405 nm, after one minute 
repeat the absorbance reading after every 1, 2, and 3 minutes. 
 
High Density Lipoprotein 
Principle:  
 The reaction between cholesterol other than HDL and the enzyme for 
cholesterol assay is suppressed by the electrostatic interaction between polyanions 
and cationic substances. Hydrogen peroxide is formed by the free cholesterol in 
HDL by cholesterol oxidase. Oxidative condensation of EMSE and 4-AA is 
caused by hydrogen peroxide in the presence of peroxidase, and the absorbance of 
the resulting red- purple quinone is measured to obtain the cholesterol value in 
HDL. HDL in the presence of polyanions and cationic substances suppress the 
reaction with enzyme. HDL (cholesterol esters) reacts with one water molecule in 
the presence of cholesterol esterase gives HDL (free cholesterol) and fatty acids. 
HDL (free cholesterol) reacts with two molecules of oxygen and one molecule of 
hydrogen ion in the presence of cholesterol oxidase gives cholestenone and 
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hydrogen peroxide. Two molecules of hydrogen peroxide react with 4-AA, 
EMSE, three molecules of hydrogen and one molecule of oxygen in the presence 
of peroxidase gives violet quinone and five molecules of water.  
Procedure:  
 Mix the reagent-1 (R1: N-ethyl-N-(3-methylphenyl)-N- 
succinylehyenediame (EMSE) and reagent-2 (R2: cholesterol oxidase 4-
aminoantipyrin(4-AA).Absorbance was recorded against reagent blank at 600 nm.  
 
LOW DENSITY LIPOPROTEIN 
 Principle: This assay method uses a surfactant for selectively solubilizing 
LDL alone in the cholesterol assay system that employs cholesterol esterase and 
cholesterol oxidase. It passes the ester cholesterol and free cholesterol contained 
in the LDL to the cholesterol reaction system to determine LDL cholesterol. The 
enzyme reactions to other, non-LDL lipoproteins (HDL, VLDL, chilomicrons) are 
inhibited by the surfactant and by the sugar compounds. These lipoproteins are 
therefore not passed to the cholesterol reaction system and consequently remain in 
the reaction liquid as lipoproteins.  
 Procedure: Mix the reagent-1(R1: HSDA-1mmol/L, good’s buffer) and 
reagent-2 (cholesterol esterase- 2.0U/L, cholesterol oxidase- 1.0mmol/L, 4-
Aminoantipyrin-2.5mmol/L and good’s buffer). Absorbance was recorded against 
reagent blank at 600 nm. 
 
VERY LOW DENSITY LIPOPROTEIN 
  The value of  VLDL was calculated by = Triglycerides/5 
 
TOTAL CHOLESTEROL 
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  To 1 ml of reagent solution (10 mM sodium cholate, 0.82 mM  
 4-aminophenazone, 6 mM phenol, 33 U/L cholesterol hydrolase, 250U/L  
cholesterol oxidase, 200 U/L horseradish peroxidase in 100 mM Tris buffer,  
(pH 7 .7 ) 10 pi serum was added. A reagent blank solution similar to reagent 
solution without the cholesterol ester hydrolase and cholesterol oxidase was 
prepared. Incubation was for about 10 min at 37°C. Absorbance was recorded at 
500 nm.  
Preparation of tissue homogenates 
 The brain was removed and washed immediately with ice-cold saline to 
remove blood. A 10% w/v brain homogenate was prepared in ice-cold potassium 
phosphate buffer (100mM, pH 7.4) followed by centrifugation at 5000g for 10 
min. the resulting supernatant was used for the estimation of biochemical 
parameters. 
A. Biochemical parameters 
1. Estimation of total protein content 
2. Estimation of malondialdehyde (MDA) 
B. Determination of enzymatic antioxidants 
3. Assay of catalase 
4. Estimation of glutathione peroxidase (GPx) 
5. Assay of superoxide dismutase (SOD) 
6. Estimation of glutathione reductase (GSSH) 
C. Determination of non-enzymatic antioxidants 
7. Estimation of reduced glutathione (GSH) 
A. Biochemical parameters 
1. Estimation of total protein content 
 To 0.1ml of brain homogenate, 4.0 ml of alkaline copper solution was 
added and allowed to stand for 10 min (Lowry et al., 1951). Then, 0.4 ml of 
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phenol reagent was added very rapidly and mixed quickly and incubated in room 
temperature for 30 min for colour development. Reading was taken against blank 
prepared with distilled water at 610 nm in UV-visible spectrophotometer. The 
protein content was calculated from standard curve prepared with bovine serum 
albumin and results were expressed as µg/mg brain tissue.(48) 
 
2. Estimation of malondialdehyde (MDA) 
 One ml of the homogenate was combined with 2 ml of TCA-TBA-HCl 
reagent (15% trichloro acetic acid (TCA) and 0.375% thiobarbituric acid (TBA) in 
0.25 N HCl) and boiled for 15 min. precipitate was removed after cooling by 
centrifugation at 1000g for 10 min and absorbance of the sample was read at 535 
nm against a blank without tissue homogenate. The levels of MDA were 
calculated using extinction coefficient calculation. The values are expressed as 
nmoles/min/mg brain tissue.(49) 
 
B. Determination of enzymatic antioxidants 
3. Assay of catalase 
 The reaction mixture contained 2.0 ml of homogenate and 1.0 ml of 30 
mM hydrogen peroxide (in 50 mM phosphate buffer, pH 7.0). a system devoid of 
the substrate (hydrogen peroxide) served as a control. Reaction was started by the 
addition of the substrate and decrease in absorbance mentioned at 240 nm for 30 
seconds at 25°C. the difference in absorbance per unit time was expressed as the 
activity and three parallel experiments were conducted. One unit is defined as the 
amount of enzyme required to decompose 1.0 M of hydrogen peroxide per minute 
at pH 7.0 and 25°C.(50) 
 
4. Estimation of glutathione peroxidase (GPx) 
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 The reaction mixture consists of 0.2 ml of 0.4 M Tris buffer, 0.1 ml of 1.0 
mM sodium azide, 0.1 ml of 0.042% hydrogen peroxide, 0.2 ml of 200 mM 
glutathione and 0.2 ml of brain tissue homogenate supernatant incubated at 37°C 
for 10 min. The reaction was arrested by the addition 0.1 ml of 10% TCA and the 
absorbance was taken at 340 nm. Activity was expressed as nmoles/min/mg brain 
protein.(51) 
 
5. Assay of superoxide dismutase (SOD) 
 The assay mixture contained 1.2 ml of sodium pyrophosphate buffer 
(0.052 M, pH 8.3), 0.1 ml of 186 µM Phenazonium methosulphate (PMS), 0.3 ml 
of 300 µM nitro blue tetrazolium chloride (NBT), 0.2 ml of 780 µM NADH, 1.0 
ml of homogenate and distilled water to a final volume of 3.0 ml. reaction was 
started by the addition of NADH and incubated at 30°C for 1 min. the reaction 
was stoped by the addition of 1.0 ml of glacial acetic acid and the mixture was 
stirred vigorously. 4.0 ml of n-butanol was added to the mixture and shaken well. 
The mixture was allowed to stand for 10 min, centrifuged, the butanol layer was 
taken out and absorbance was measured at 560 nm against a butanol blank. A 
system devoid of enzyme served as the control and three parallel experiments 
were conducted. (52) 
 
6. Estimation of glutathione reductase (GSSH) 
 The enzyme activity was determined spectrophotometrically by the 
decrese in absorbance of NADPH at 340 nm. The reaction mixture contained 2.1 
ml of 0.25 mM potassium phosphate buffer pH 7.6, 0.1 ml of 0.001 M NADPH, 
0.2 ml of 0.0165 M oxidized glutathione and 0.1 ml of bovine serum albumin (10 
mg/ml). The reaction was started by the addition of 0.02 ml of brain tissue 
homogenate with mixing and the decrease in absorbance at 340 nm was measured 
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for 3 min against a blank. Glutathione reductase activity was expressed as 
nmoles/min/mg brain protein at 30°C. (53) 
 
C.  Determination of non-enzymatic antioxidants 
Estimation of reduced glutathione (GSH) 
 Brain was homogenized in 10% w/v cold 20mM EDTA solution on ice. 
After deproteinization with 5% TCA, an aliquot of the supernatant was allowed to 
react with 150 µM DTNB. The product was detected and quantified 
spectrophotometrically at 416 nm. Pure GSH was used as standard for establishing 
the calibration curve and three parallel experiments were conducted.(54) 
Histopathological studies 
 The portions of heart and liver were immersed in 10% formalin for 24 h 
for histopathological examination. The specimens were cleared in xylene and 
embedded in paraffin. Paraffin bees wax blocks were prepared and cut into 5µM 
thick sections. The obtained tissue sections were mounted on glass slides and 
stained with hematoxylin and eosin for histopathological examination using a light 
microscope. 
Statistical analysis 
 The results would be statistically analyzed by One way-ANOVA followed 
by Tukey’s test using GraphPad Instat software. The values would be expressed as 
mean ± SEM. P<0.05 would be considered statistically significant when compared 
to standard and negative control. 
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RESULTS 
PHYTOCHEMICAL SCREENING 
                  Phytochemical screening of powdered leaves of Anisomeles malabari-
ca showed the presence of  alkaloids, flavonoids, saponins, tannins, sterols, oil 
and fat, phenolic compound, protein and amino acid, gums and mucilages, carbo-
hydrates, and glycosides.(Table-6) 
Table 6: Phytochemical screening 
S.No Phytochemical Interpretation 
   1 Alkaloid + 
   2 Flavonoids + 
   3 Saponins + 
   4 Tannins + 
   5 Sterols + 
   6 Oil and Fat - 
   7 Phenolic compound + 
   8 Protein and Aminoacid + 
   9 Gums and mucilage + 
  10 Carbohydrates + 
  11 Glycosides + 
                   (+) Present; (-) Absent 
GC-MS Analysis 
 Gas chromatography mass spectroscopy analysis was carried out in a crude 
leaf ethanolic extract of Anisomeles malabarica. The total ion chromatogram 
(TIC) of ethanol extract of A.malabarica showing the GC-MS profile of the com-
pounds were identified. The peaks in the chromatogram were integrated and were 
compared with the database of spectrum of known components stored in the GC-
MS library.  
 The detailed tabulations of GC-MS analysis of the extracts are given be-
low. Phytochemical analysis by GCMS analysis of the plant extract revealed the 
presence of different fatty acids, heterocyclic compounds etc. 
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IN VITRO STUDIES 
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Cholesterol esterase inhibitory activity 
 The ethanolic leaf extract of Anisomeles malabarica was studied for its 
cholesterol esterase inhibitory activity at various concentrations ranging from 10, 
20, 40, 80, 160, and 320 µg/ml. The absorbance of the mixture was measured at 
405nm. It was observed that there is a dose dependent increase in the percentage 
inhibition from the concentration 10µg/ml to 320 µg/ml and the values are shown 
Table-7. IC50 values of the extract was calculated and compared with the standard 
Gallic acid. 
 For the extract of AMLE IC50 value was calculated and was found to be 
46.66±11.66µg/ml.Gallic acid is used as a reference standard and IC50 value was 
found to be 45.66±10.039µg/ml. 
Table 7:    Cholesterol esterase inhibitory activity of Gallic acid 
Concentration 
(µg/ml) 
% Inhibition 
Mean ± SEM IC50(µg/ml) 
I II III 
5 3.72 26.69 51.52 27.31±13.802 
45.66±10.039 
 
10 6.07 38.78 57.78 34.21±15.101 
20 43.0 23.83 46.77 37.866±7.102 
40 20.02 38.78 56.92 38.573±10.653 
80 28.6 32.46 69.04 43.366±12.885 
160 26.15 62.23 65.53 51.303±12.613 
320 37.51 52.42 69.24 53.056±9.165 
Results are Mean ± SEM of two parallel measurements values 
                      Table 8:    Cholesterol esterase inhibitory activity of AMLE 
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Concentration(µg/ml) 
% Inhibition 
Mean ± SEM IC50(µg/ml) 
I II III 
5 16.06 40.09 58.14 38.096±12.188 
 
 
 
 
46.66±11.667 
 
 
 
10 20.88 50.98 58.76 43.54±11.550 
20 71.29 58.16 24.84 51.43±13.825 
40 34.74 52.21 61.88 49.61±7.942 
80 42.03 49.02 60.34 50.46±5.335 
160 25.9 59.93 64.48 50.10±12.173 
320 37.64 53.56 69.33 53.51±9.148 
Results are Mean ± SEM of two parallel measurements values. 
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IN VIVO STUDIES 
Acute toxicity studies and selection of dose for in vivo studies 
Acute toxicity was determined as per OECD guidelines (420) using fixed 
dose procedure for fixing the dose for biological activity. For acute toxicity stud-
ies ten female rats weighing 150-200g were taken and they were fasted overnight 
before the experimental day. Overnight fasted rats were weighed and body weight 
determined for dose calculation and the test samples (AMLE) were administered 
orally starting with a lower dose of 5 mg/kg in 0.5 % CMC and the dose was 
gradually increased in a sequence of 50, 300 and 2000 mg/kg and the signs and 
symptoms of toxicity and death if any were observed individually at 0, 0.5, 1, 2, 3 
and 4h for first 24 h and thereafter daily for 14 days. Food was given to the ani-
mals after 4 h of dosing. The animals were observed twice daily for 14 days and 
body weight changes, food and water consumption, etc.were noted.  
In acute toxicity studies, it was found that the animals were safe up to a 
maximum dose of 2000 mg/kg of body weight. There were no changes in normal 
behavioral pattern and no signs and symptoms of toxicity and mortality were ob-
served up to the dose of 2000 mg/kg body weight Table-9 & Table-10. Hence, as 
per the OECD 420 guidelines AMLE can be included in the category 5 or unclas-
sified category of globally harmonized classification system (GHS). Hence, based 
on these results the AMLE was considered non-toxic and for the biological evalu-
ation the dose of 50 and 100 mg/kg body weight was selected. 
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Table 9 : OBSERVATIONS DONE FOR THE ACUTE ORALTOXICITY STUDY OF AMLE 
Parameters observed 0 h 0.5h 1 h 2 h 4 h Day 2&3 
Day 
4&5 
Day 
6&7 
Day 
8&9 
Day 
10&11 
Day 
12&13 
Day 
14 
Respiratory 
Dyspnea - - - - - - - - - - - - 
Apnea - - - - - - - - - - - - 
Nostril discharges - - - - - - - - - - - - 
Motor 
activity 
Tremor - - - - - - - - - - - - 
Hyper activity - - - - - - - - - - - - 
Hypo activity - - - - - - - - - - - - 
Ataxia - - - - - - - - - - - - 
Jumping - - - - - - - - - - - - 
Catalepsy - - - - - - - - - - - - 
Locomotor activity - - - - - - - - - - - - 
Reflexes 
Corneal reflex + + + + + + + + + + + + 
Pinna reflex + + + + + + + + + + + + 
Righting reflex + + + + + + + + + + + + 
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Table 9 : OBSERVATIONS DONE FOR THE ACUTE ORALTOXICITY STUDY OF AMLE contd…….. 
Parameters observed 0 h 0.5h 1 h 2 h 4 h Day 2&3 
Day 
4&5 
Day 
6&7 
Day 
8&9 
Day 
10&11 
Day 
12&13 
Day 
14 
Convulsion Tonic and clonic 
convulsion - - - - - - - - - - - - 
Muscle tone Hypertonia - - - - - - - - - - - - Hypotonia - - - - - - - - - - - - 
Ocular sign 
Lacrimation - - - - - - - - - - - - 
Miosis - - - - - - - - - - - - 
Mydriasis - - - - - - - - - - - - 
Ptosis - - - - - - - - - - - - 
Skin 
Edema - - - - - - - - - - - - 
Skin and fur - - - - - - - - - - - - 
Erythema  - - - - - - - - - - - 
Cardiovascular 
signs 
Bradycardia - - - - - - - - - - - - 
Tachycardia - - - - - - - - - - - - 
Piloerection 
Contraction of 
erectile tissue of 
hair 
- - - - - - - - - - - - 
Gastro intestinal 
signs Diarrhea - - - - - - - - - - - - 
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                                      TABLE 10 :  LIVE PHASE OBSERVATION 
Live phase animals Observations 
1. Body weight every day Normal 
2. Food consumption daily Normal 
3. Water consumption daily Normal 
 4.    Home cage activity Normal 
Note: Acute toxicity study of AMLE was performed and it was non-toxic up to 2000 
mg/kg dose 
Table 11:MORTALITY RECORD FOR AMLE IN ACUTE ORAL  
TOXICITY STUDY 
Group Group 1  (5 mg/kg) 
Group 2  
(50 mg/kg) 
Group 3 
 (300 mg/kg) 
Group 4  
(2000 mg/kg) 
No. of animals 1 1 1 1 2 
Body weight (g) 150 183 180 200 195 
Sex Female Female Female Female Female 
30 min Nil Nil Nil Nil Nil 
1 h Nil Nil Nil Nil Nil 
2 h Nil Nil Nil Nil Nil 
3 h Nil Nil Nil Nil Nil 
4 h Nil Nil Nil Nil Nil 
Day 1 Nil Nil Nil Nil Nil 
Day 2 Nil Nil Nil Nil Nil 
Day 3 Nil Nil Nil Nil Nil 
Day 4 Nil Nil Nil Nil Nil 
Day 5 Nil Nil Nil Nil Nil 
Day 6 Nil Nil Nil Nil Nil 
Day 7 Nil Nil Nil Nil Nil 
Day 8 Nil Nil Nil Nil Nil 
Day 9 Nil Nil Nil Nil Nil 
Day 10 Nil Nil Nil Nil Nil 
Day 11 Nil Nil Nil Nil Nil 
Day 12 Nil Nil Nil Nil Nil 
Day 13 Nil Nil Nil Nil Nil 
Day 14 Nil Nil Nil Nil Nil 
Mortality 0/1 0/1 0/1 0/2 
Note: Acute toxicity study of AMLE was performed and it was non-toxic up to 
2000 mg/kg dose 
Effect of the extract of A.malabarica on Body weight 
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 The comparison of body weight between the first day of the study and last 
day, showed significant increase in the body weight in all groups.And the HCD 
group is increases when compare to the other groups. Statistical analysis of the 
results using Student’s paired T test showed that the values obtained are signifi-
cant          P values P<0.05. 
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Table 12: Effect of AMLE on Body weight 
 
Group Name 
Body weight (g) 
Initial Final  
Normal control 160.83±4.54 200±6.51* 
Negative control 199.16±14.17 265±10.40* 
AMLE low dose(100 mg/kg) 146±6.96 213.33±3.33* 
AMLE high dose(200 mg/kg) 154.16±7.35 228±9.165* 
AMLE alone(200 mg/kg) 153.33±3.57 170±6.83* 
Standard Atorvastatin(10 mg/kg) 141.6±4.77 222±8.29* 
Values are expressed as mean ±SEM (n=6).* denotes P<0.05 When compared to the initial readings (Student’s Paired ‘t’ -test)
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Average Food Intake 
 Quantities of food consumed by rats in group I were more when compared 
to remaining groups, this was because rats were fed with extra HFD for 1 to 25 
days during hyerlipidemia induction. The quantities of food intake were the same 
in all groups, although body weight gain differed significantly between control 
groups, standard and AMLE treated groups. This difference was probably due to 
the different doses of AMLE extracts seems to exert a protective effect against 
overweight in AMLE treated group as compared to HFD control group. The val-
ues of average feed intake were tabulated in Table No 13. 
Table No 13: Effect of AMLE on Food Intake in HFD  
Induced Hyperlipidemic Rats. 
Groups Treatment Average food intake 1-25 days(gm) 
Average food intake 
25-50 days(gm) 
Group I Normal control 17.28±0.303 15.83±0.215 
Group II Negative control 10.42±0.375 16.64±0.648 
Group III AMLE  low dose (100mg/kg) 10.04±0.426 16.62±0.693 
Group IV AMLE high dose (200 mg/kg) 9.99±0.474 16.95±427 
Group V AMLE alone (200 mg/kg) 15.20±0.56 14.50±0.35 
Group VI Standard (10 mg/kg) 10.25±0.250 17.29±0.500 
Effect of extract of A.malabarica on water consumption 
 During the treatment, A.malabarica extract caused a significant increase in 
water consumption. The amount of water intake were the same in all groups,  
although there will differed significantly between control groups, standard and 
AMLE treated groups. This difference was probably due to the different doses of 
AMLE extracts. The values of average water intake were tabulated in  
Table No 14. 
Table No 14: Effect of AMLE on water consumption in HFD  
Induced Hyperlipidemic Rats. 
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Groups Treatment Average water in-take 1-25 days(ml) 
Average water intake 
25-50 days(ml) 
Group I Normal control 100.50±3.0 120.10±8.50 
Group I Negative control 106.8±1.41 141.89±1.02 
Group III AMLE  low dose (100mg/kg) 187.04±1.23 222.04±1.14 
Group IV AMLE high dose (200 mg/kg) 141.68±2.11 281.82±2.13 
Group V AMLE alone (200 mg/kg) 110.12±5.60 130.58±60 
Group VI Standard (10 mg/kg) 45.95±2.22 74.15±1.33 
 
Serum Biochemical Parameters 
 The lipid profile was evaluated by estimating triglycerides (TG), total cho-
lesterol (TC), HDL-Cholesterol (HDL-C), LDL-Cholesterol (LDL-C) and VLDL-
Cholesterol (VLDL-C) in   normal and hyperlipidemic animals. The values were 
tabulated in Table No.  
Triglycerides (TG) 
 Animals in HFD group exhibited significant (P<0.001) increase in triglyc-
eride levels (394.3±2.389mg/dl) compared to normal control group 
(164.98±6.50mg/dl). 
 Hyperlipidemic animals treated with 100mg/kg AMLE showed significant 
(P<0.05) reduction in triglycerides levels, animals treated with 200mg/kg AMLE 
showed significant (P<0.01) decrease in triglycerides levels. And animals treated 
with AMLE alone group shows non-significant (P>0.05) in triglycerides level. 
 
 
Total cholesterol (TC) 
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 Animals in HFD group exhibited significant (P<0.05) increase in total cho-
lesterol levels (193.4±mg/dl) compared to normal control group 
(122.8±2.18mg/dl). Hyperlipidemic animals treated with 100mg/kg AMLE did 
not show significant reduction in total cholesterol levels, animals treated with 
200mg/kg AMLE showed significant ( P<0.01 ) decrease in total cholesterol lev-
els 180.3±3.21mg/dl and animals treated with AMLE alone group shows non- 
significant (P>0.05) when compared to the negative control.  
High Density Lipoprotein (HDL) 
 Animals in HFD group exhibited significant (P<0.05) decrease in HDL 
levels (2.130±0.006mg/dl) compared to normal control group (3.513±0.32mg/dl). 
 Hyperlipidemic animals treated with 100mg/kg AMLE did not shown sig-
nificant increase in HDL levels, animals treated with 200mg/kg AMLE showed 
significant (P<0.05) increase in HDL levels and animals treated with AMLE alone 
group shows non- significant (P>0.05) when compared to the negative control.  
Low Density Lipoprotein (LDL) 
 Animals in HFD group exhibited significant (P<0.1) increase in LDL lev-
els (101.0±3.33mg/dl) compared to normal control group (54.38±2.94mg/dl). 
 Hyperlipidemic animals treated with 100mg/kg and 200mg/kg AMLE did 
not show significant reduction in LDL levels, and animals treated with AMLE 
alone group shows non- significant(P>0.05) when compared to the negative con-
trol.  
 
 
Very Low Density Lipoprotein (VLDL) 
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 Animals in HFD group exhibited significant(P<0.05) increase in VLDL 
levels (68.81±0.92mg/dl) compared to normal control group (28.38±0.74mg/dl). 
 Hyperlipidemic animals treated with 100mg/kg AMLE showed significant 
(P<0.01) reduction in VLDL levels 64.20±0.59mg/dl, animals treated with 
200mg/kg AMLE showed extremely significant decrease in VLDL levels, 
34.62±0.90 respectively P<0.001. 
 Standard drug Atorvastatin treated group showed potent antihyperlipidem-
ic activity and showed decrease in triglyceride, total cholesterol, LDLc, VLDLc 
levels, increase in HDL c levels with extreme significance compared to HFD con-
trol group. 
Serum Marker Enzymes 
 The activities of serum marker enzymes like AST, ALT, ALP and LDH 
were significant (P<0.05) increases in the HFD group when compared to the nor-
mal control groups. Hyperlipidemic animals treated with 100mg/kg and 200mg/kg 
AMLE  shown significant reduction in LDL levels, and animals treated with AM-
LE alone group shows non- significant (P>0.05) when compared to the negative 
control.  
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Table 15:Effect of AMLE on Serum  Biochemical Parameters 
 
Groups 
 
Treatment 
Serum lipid profile (mg/dl) 
TC TG ALP LDH SGOT SGPT HDL-C LDL-C VLDL-C 
Group 
I 
Vehicle con-
trol 
122.8 
±2.18 
164.9 
±6.50 
0.26 
±.015 
1.33 
±0.18 
3.65 
±0.77 
3.004 
±0.82 
3.51 
±0.32 
54.3 
±2.94 
28.38 
±0.74 
Group 
II 
Negative 
Control 
193.4 
±2.61 
394.3 
±2.38### 
2.46 
±0.15### 
2.13 
±0.006# 
16.41 
±4.9# 
10.62 
±1.81### 
2.13 
±0.006# 
101.0 
±3.3# 
68.81 
±0.92# 
Group 
II 
AMLE 
low dose 
(100 mg/kg) 
193.4 
±2.61 
178.51 
±9.60*** 
0.64 
±0.03*** 
0.45 
±0.02*** 
2.14 
±0.29*** 
0.025 
±0.00*** 
0.26 
±0.07** 
98.85 
±3.95*** 
64.20 
±0.59*** 
Group 
IV 
AMLE 
high dose 
(200 mg/kg) 
180.3 
±3.21** 
144.14 
±9.99** 
0.68 
±0.04*** 
0.48 
±0.19*** 
3.178 
±1.18** 
0.03 
±0.003*** 
0.35 
±0.07** 
60.51 
±2.67*** 
34.62 
±0.90*** 
Group 
V 
AMLE alone 
(200 mg/kg) 
119.5 
±1.90ns 
208.5 
±24.22ns 
0.40 
±0.03ns 
1.63 
±0.18ns 
8.71 
±1.78ns 
2.55 
±1.16ns 
2.38 
±0.56ns 
50.40 
±1.86ns 
25.40 
±0.56ns 
Group 
VI 
Standard 
(10 mg/kg) 
129.4 
±2.26*** 
206.01 
±14.64*** 
0.52 
±0.10*** 
0.46 
±0.10*** 
3.92 
±0.871** 
0.03 
±0.004*** 
3.46 
±0.07* 
58.01 
±1.38*** 
32.90 
±0.55*** 
 Values are expressed in Mean ± SEM (n=6) one way ANOVA followed by Tukey’s test. Where, # denotes P<0.05 and ### de-
notes P<0.001 when compared to vehicle control rats.*denotes P<0.05, **denotes P<0.01 and ***denotes P<0.001 when compared to 
negative control. nsdenotes P>0.05 when compared to vehicle control group. 
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Effect of AMLE on Total protein and MDA 
 There was a significant (P<0.05) decrease in the level of total protein and 
MDA in Negative control group when compared to the normal control groups. 
(Table No.16) 
 When the AMLE treated groups shows significant (P<0.05) in the Total 
protein and MDA in the tissues (heart and liver)  homogenate  in the dose 100 and 
200 mg/kg when compared to the Negative control group (HFD).AMLE alone 
treated groups shows non-significant (P>0.05) when compare to the normal con-
trol groups. 
Effect of AMLE on enzymatic and non-enzymatic antioxidants in control and 
experimental groups 
 High Fat Diet animals shows a significant (P<0.05) decrease in the enzy-
matic antioxidants like catalase, superoxide dismutase, glutathione peroxidase and 
glutathione reductase and the non-enzymatic antioxidant reduced glutathione in 
the  tissues (heart and liver) homogenate when compared to normal control.(Table 
No16.) 
 When the AMLE treated groups shows significant (P<0.05) in the enzy-
matic antioxidants like catalase, superoxide dismutase, glutathione peroxidase and 
glutathione reductase and the non-enzymatic antioxidant reduced glutathione in 
the tissue (heart and liver) homogenate in the dose 100 and 200 mg/kg when com-
pared to the Negative control group (HFD).AMLE alone treated groups shows 
non-significant (P>0.05) when compare to the normal control groups. 
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Table 16: Effect of AMLE on the lipid peroxidation and antioxidant enzymes in Liver 
GROUPS Total protein MDA SOD CAT GSH GSSH GPX 
Normal control 14.51 
±0.56 
0.41 
±0.098 
2.660 
±0.310 
2.498 
±0.219 
1.813 
±0.408 
1.581 
±0.243 
3.06 
±0.416 
Negative control 7.95 
±1.07### 
0.014 
±0.004### 
0.028 
±0.004### 
0.073 
±0.010### 
0.043 
±0.005## 
0.023 
±0.003### 
0.054 
±0.003### 
AMLElow dose(100mg/kg) 2.45 
±1.39* 
0.253 
±0.055* 
1.54 
±0.2183*** 
1.388 
±0.202** 
1.75 
±0.167** 
1.095 
±0.020*** 
1.504 
±0.403* 
AMLEhigh dose(200 
mg/kg) 
9.02 
±0.71** 
0.37 
±0.070** 
1.595 
±0.236*** 
1.404 
±0.230** 
1.948 
±0.23** 
0.9054 
±0.0206** 
1.895 
±0.187** 
AMLE alone(200 mg/kg) 12.44 
±1.0ns 
0.191 
±0.017ns 
1.892 
±0.166ns 
1.604 
±0.238ns 
1.734 
±0.355ns 
1.518 
±0.2437ns 
1.979 
±0.1941ns 
Standard(10 mg/kg) 7.23 
±1.57* 
0.306 
±0.012* 
2.24 
±0.021*** 
1.995 
±0.390*** 
1.36 
±0.340* 
1.06 
±0.0092*** 
1.55 
±0.244* 
Protein = mmoles/min/mg, CAT = mmoles/min/mg wet protein, GPx = µmoles/min/mg protein, SOD = µmoles/min/mg protein, 
GSSH = µmoles/min/mg protein,GSH = µmoles/min/mg protein,  and MDA = µmoles/min/mg protein ;Values are expressed in Mean ± 
SEM (n=6) one way ANOVA followed by Tukey’s test. Where, # denotes P<0.05 and ### denotes P<0.001 when compared to vehicle 
control rats.*denotes P<0.05, **denotes P<0.01 and ***denotes P<0.001 when compared to negative control. nsdenotes P>0.05 when 
compared to vehicle control group. 
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                                         Table 17: Effect of AMLE on lipid peroxidation and antioxidant enzymes in Heart 
GROUPS Total protein MDA SOD CAT GSH GSSH GPX 
Normal control 12.51 
±0.56 
0.351 
±0.090 
2.77 
±0.393 
2.946 
±0.271 
2.276 
±0.306 
1.88 
±0.278 
2.74 
±0.322 
Negative control 76.95 
±1.07### 
0.034 
±0.005## 
0.049 
±0.013### 
0.070 
±0.010### 
0.031 
±0.0048### 
0.0380 
±0.009### 
0.090 
±0.03### 
AMLE 
Low dose    (100mg/kg) 
1.45 
±1.39* 
0.330 
±0.07* 
1.832 
±0.281*** 
1.44 
±0.210** 
1.962 
±0.259*** 
1.766 
±0.157** 
1.435 
±0.174* 
AMLE 
High dose    (200 mg/kg) 
5.02 
±0.71** 
0.634 
±0.070*** 
1.72 
±0.20*** 
1.419 
±0.216** 
2.101 
±0.422*** 
1.642 
±0.4622** 
1.611 
±0.32* 
AMLE alone 
(200 mg/kg) 
10.44 
±1.0ns 
0.247 
±0.017ns 
2.055 
±0.1791ns 
2.0994 
±0.23ns 
1.686 
±0.3006ns 
1.3188 
±0.1652ns 
1.97 
±0.23ns 
Standard 
(10 mg/kg) 
6.23 
±1.57* 
0.312 
±0.024* 
2.156 
±0.2110*** 
2.079 
±0.379*** 
1.7006 
±0.277** 
1.678 
±0.331** 
1.66 
±0.2610* 
 Protein = mmoles/min/mg, CAT = mmoles/min/mg wet protein, GPx = µmoles/min/mg protein, SOD = µmoles/min/mg protein, GSSH 
= µmoles/min/mg protein, GSH = µmoles/min/mg protein, and MDA = µmoles/min/mg protein ;Values are expressed in Mean ± SEM 
(n=6) one way ANOVA followed by Tukey’s test. Where, # denotes P<0.05, ## denotes P<0.01 and ### denotes P<0.001 when com-
pared to vehicle control rats.*denotes P<0.05, **denotes P<0.01 and ***denotes P<0.001 when compared to negative control. nsdenotes 
P>0.05 when compared to vehicle control group. 
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Histopathological changes in Heart 
Normal control 
 Section studied from heart shows normal myocardium with myocytes. The 
blood vessels show normal. There is no evidence of architectural destruction/ 
edema/ inflammatory infiltrates/ necrosis.(Figure-1) 
Negative control 
 Section studied from heart shows normal myocardium with architecture. 
Stroma shows focal cytoplasmic vacuolation and also shows scattered lymphocyt-
ic infiltration. The blood vessels show normal morphology.(Figure-2) 
AMLE low dose (100 mg/kg) 
 Section studied from heart shows myocardium with myocytes showing 
cytoplasmic vacuolation (fatty change). The blood vessels show normal morphol-
ogy. There is no evidence of architectural destruction/ edema/ inflammatory infil-
trates/ necrosis. (Figure-3) 
AMLE high dose (200 mg/kg) 
 Section studied from heart shows normal myocardium with myocytes. The 
blood vessels show congestion. There is no evidence of architectural destruction/ 
edema/ inflammatory infiltrates/ necrosis. (Figure-4) 
AMLE alone (200 mg/kg) 
 Section studied from heart shows normal myocardium with myocytes. The 
blood vessels show normal. There is no evidence of architectural destruction/ 
edema/ inflammatory infiltrates/ necrosis. (Figure-5) 
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 Standard(10 mg/kg) 
 Section studied from heart shows normal myocardium with myocytes. The 
blood vessels show congestion. There is no evidence of architectural destruction/ 
edema/ inflammatory infiltrates/ necrosis.(Figure-6) 
               
 
       
 
 
 
 
 
Figure-1 Photomicrograph of 
heart tissues from normal 
 control group 
  
Figure-2 Photomicrograph of-
heart tissues from negative con-
trol group 
  
Figure-3 Photomicrograph of 
heart tissues from  
AMLE Low dose 
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Figure-4 Photomicrograph of  heart tissues from 
Standard  
 
 
Histopathological changes in Liver 
Figure-4 Photomicrograph of 
heart tissues from 
AMLE High dose
Figure-5 Photomicrograph of  
heart tissues from 
 AMLE  alone  
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Normal control 
The sections from the liver shows normal lobular architecture. Individual 
hepatocytes show no significant pathology. Portal traid shows normal morpholo-
gy. Sinusoids show mild dilatation. Central vein shows normal. (Figure-7) 
Negative control: 
The sections from the liver shows mild altered architecture. Individual 
hepatocytes show cytoplasmic vacuolation. Portal traid shows bile duct hyperplas-
ia. Sinusoids show mild dilatation congestion. Central vein shows congestion. 
(Figure-8) 
AMLE low dose (100mg/kg) 
The sections from the liver shows altered lobular architecture. Individual 
hepatocytes show cytoplasmic vacuolation( both micro and macro vesicular stea-
tosis). Portal traid shows bile duct hyperplasia. Sinusoids show mild dilatation. 
Central vein shows no significant abnormality. (Figure-9) 
AMLE High dose (200 mg/kg) 
The sections from the liver shows normal lobular architecture. Individual 
hepatocytes show no significant pathology. Portal traid shows bile duct hyperplas-
ia. Sinusoids show mild dilatation. Central vein shows dilatation and congestion. 
(Figure-10) 
AMLE alone (200 mg/kg) 
The sections from the liver shows normal lobular architecture. Individual 
hepatocytes show no significant pathology. Portal traid shows mild bile duct  
hyperplasia. Sinusoids show mild dilatation. Central vein shows congestion.  
(Figure-11) 
Standard (10 mg/kg) 
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The sections from the liver shows normal lobular architecture. Individual 
hepatocytes show no significant pathology. Portal traid shows mild periportal in-
flammation and bile duct hyperplasia. Sinusoids show mild dilatation. Central 
vein shows normal. (Figure-12) 
                
 
 
 
Figure-9 
Figure-7 Photomicrograph of  
liver tissues isolated from normal 
 control group 
Figure-8 Photomicrograph of  
liver tissues  from negative con-
trol group 
Figure-9 Photomicrograph of liv-
er tissues from  
AMLE Low dose 
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Figure-12 Photomicrograph of liver tissues from 
Standard  
 
Figure-10 Photomicrograph of  
liver tissues from 
 AMLE  High dose  
Figure-11 Photomicrograph of  
liver tissues from 
 AMLE  alone  
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DISCUSSION AND CONCLUSION 
       Hypercholesterolemia and the resulting atherosclerosis have been 
implicated in the pathophysiology of coronary heart diseases and myocardial 
ischemia. Lowering cholesterol level may decrease the risk of CVD, and therefore 
enormous efforts have been extended to achieve this aim. The 
hypocholesterolemic activity of ethanolic leaf extract of Anisomeles malbarica  
(AMLE) against hypercholesterolemia was monitored on the Lipid profile status, 
antioxidant status, activities of serum cardiac marker enzyme, and histological 
changes of liver and heart.  In this study the high cholesterol diet (HCD) is used 
which consists of maize, soya meal, coconut cake, rice polish, groundnut cake and 
animal fat such as tallow which has been used in inducing experimental 
hypercholesterolemia.(46) In the current study, the HCD fed rats showed increased 
levels of plasma cholesterol (TC), and triglycerides (TG) levels compared to 
normal control rats. Treatment with AMLE significantly decreased the levels of 
serum TC, TG, when compared to HCD induced rats. 
 Saponins are also reported to precipitate cholesterol from micelles and 
interfere with enterohepatic circulation of bile acids making it unavailable for 
intestinal absorption, this forces liver to produce more bile from cholesterol and 
hence the reduction in serum cholesterol level. Saponins are also reported to lower 
triglycerides by inhibiting pancreatic lipoprotein lipase. Similarly in our study 
also, the presence of both flavanoids and saponins in AMLE could have 
contributed in reducing the levels of lipid status (TC, TG,) elevated levels of 
serum low density lipoprotein cholesterol (LDL) and very low density lipoprotein 
cholesterol (VLDL) are often accompanied by premature atherosclerosis and other 
CVD. A low level of high-density lipoprotein cholesterol (HDL) is also an 
important risk factor for cardiovascular disease.  
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 The cardioprotective effects of HDL have been attributed to its role in 
reversing cholesterol transport, its effects on endothelial cells, and its antioxidant 
activity. Flavanoids can increase HDL-C and also decreases oxidation of LDL-
cholesterol. High cholesterol diet increases serum LDL levels and oxidative stress 
which results in the production of increased oxidized LDL and thereby increases 
atherosclerotic plaque formation. From our present study it is evident that HCD 
induced rats showed increased serum LDL and VLDL levels with the concomitant 
reduction in serum HDL level, when compared to normal rats. Supplementation 
with AMLE reduced the serum LDL and VLDL levels and increased the serum 
HDL level which could be due to reduction in plasma total cholesterol and 
increasing LDL receptor activity by the flavanoids and phytosterol present in the 
plant extract. Also it could be presumed that the reduction of total cholesterol by 
AMLE could have been associated with a reduction of its LDL fraction, which is 
the target of several hypolipidemic drugs. Oxidative stress is believed to 
contribute to the pathogenesis of hypercholesterolemic atherosclerosis hence, 
various antioxidant compounds are being evaluated for potential anti-
hypercholesterolemic effects.  
 A high fat diet brings about remarkable modifications in the antioxidant 
defence mechanisms of rat tissues by the process of lipid peroxidation. Several 
reports have shown that hypercholesterolemia diminishes the antioxidant defence 
systems by producing free radicals and thereby elevating the lipid peroxide 
products, resulting in the production of toxic intermediates. Superoxide dismutase 
is the first enzyme in antioxidant defense that protects tissues against oxygen free 
radicals by catalyzing the removal of superoxide radical (O2.-), which damages the 
membrane and biological structures.Catalase has been shown to be responsible for 
the detoxification of significant amounts of Hydrogen
 
peroxide.(50) SOD and CAT 
are the two major scavenging enzymes that remove the toxic free radicals. From 
our study we observed that there was a reduction in the activity of  hepatic SOD 
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and CAT in HCD induced rats  when compared to control rats , this may be due to 
the enhanced production of Reactive Oxygen Species (ROS) by HCD. This free 
radical affects the antioxidant activity and hence resulted in the decreased activity 
of SOD and CAT.(50-52) 
 Treatment with AMLE restores the HCD induced alteration in the activity 
of the SOD and CAT to near control due to its free radical scavenging activity.  
GPx has been shown to be responsible for the detoxification of H2O2. Glutathione 
reductase is responsible for the reduction of oxidised glutathione to glutathione 
(reduced). The increased oxidant stress in hypercholesterolemic conditions 
exhausts the GSH pools. Activities of hepatic antioxidant enzymes viz., 
Glutathione peroxidase (GPx) and Glutathione Reductase (GR) enzymes and 
Glutathione contents were significantly decreased in HCD induced rats. On oral 
administration with AMLE, the activities of these antioxidant enzymes in liver 
were reverted back to normal levels. Earlier it has been reported that AMLE has 
an antioxidant activity owing to the presence of its saponins, flavanoids and 
phytosterol.  
 Lipid peroxidation is regarded as one of the basic mechanisms of cellular 
damage caused by free radicals. The relationship between LPO and 
hypercholesterolemia is well recognized, a cholesterol rich diet results in 
increased LPO by the induction of free radical production. Hypercholesterolemia 
and lipid peroxidation are believed to be critically involved in development of 
atherosclerosis. In our study we found that a significant increase in LPO levels 
were observed in HCD fed groups when compared to the control group. AMLE 
brought down the level of LPO to near normal. It has been already reported that 
AMLE has an antioxidant activity owing to the presence of its saponins, 
flavanoids and phytosterol, thus it decrease the concentration of free radicals, 
which might terminate the initiation and propagation of LPO. (49)Several reports 
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showed that high cholesterol level can cause cardiac damage. Elevation in the 
levels of diagnostic marker enzymes such as Alanine transaminase, Aspartate 
transaminase, Lactate dehydrogenase in serum of HCD induced rats is due to 
Peroxide formation induced by hypercholesterolemia in the form of ROS. This 
ROS production increases cellular membrane permeability, intracellular fluid 
transfers onto intercellular space, resulting in muscle and cardiac damage which 
leads to the leakage or release of marker enzymes from cardiac tissue to serum 
and hence the level of marker enzymes are raised in HCD fed rats. There was a 
significant elevation in the levels of marker enzymes such as SGOT, SGPT, LDH 
were observed in HCD induced rats when compared with control rats. Treatment 
with AMLE significantly reduced the activity of SGOT, SGPT,LDH to near 
normal levels.  Macroscopic observation of liver and heart showed that tenacity of 
vessel in control group was better than that of hypercholesterolemic rats.  
Furthermore, surface of intima in rats fed with normal rat chow was smooth and 
glossy, and there is no thickening of the intima or migration of smooth muscle 
cells to the intima, whereas surface of intima of HCD induced rats showed a 
typical plaque characterized by thickening of the intima, migration of smooth 
muscle cells to the intima, infiltration of macrophages, appearance of foam and 
lamellar calcification under the endothelium.    
 From our result we observed that there was an increased foam cell 
formation which leads to intimal thickening in HCD induced group. These foam 
cell counts were reduced in AMLE treated group which could be due to its 
inhibition activity on cholesteryl ester and thereby reduces the specific binding 
sites of acetyl LDL hence can reduce the foam cell formation and leads to less 
thickening of intima.  The result obtained in this study suggests that the ethanolic 
extract of A.malabarica has beneficial effects in preventing hypercholesterolemia 
by lowering lipid status, improving antioxidant status as well as protecting the 
heart and liver morphology.  The present experimental data therefore suggest that 
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ethanolic extract of A.malabarica has an atheroprotective potential. Further 
studies using various other models has to be carried out to confirm these findings. 
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